Published in final edited form as:

Front Biosci (Landmark Ed). ; 18: 241–278.

The power of yeast to model diseases of the powerhouse of the cell

Matthew G. Baile¹ and Steven M Claypool¹

¹Department of Physiology, Johns Hopkins School of Medicine, Baltimore, MD 21205-2185

Abstract

Mitochondria participate in a variety of cellular functions. As such, mitochondrial diseases exhibit numerous clinical phenotypes. Because mitochondrial functions are highly conserved between humans and *Saccharomyces cerevisiae*, yeast are an excellent model to study mitochondrial disease, providing insight into both physiological and pathophysiological processes.

Keywords

Mitochondria; Oxidative Phosphorylation; Mitochondrial Disease; *Saccharomyces cerevisiae*; Review

2. INTRODUCTION

While the mitochondrion is best known for its ability to synthesize ATP through oxidative phosphorylation (OXPHOS), it additionally participates in a number of fundamental cellular processes, including ion regulation, heme and Fe/S cluster synthesis, lipid metabolism, signal transduction, and programmed cell death.

Mitochondrial function requires the coordination of both the nuclear and mitochondrial genomes. Of the estimated 1000–1500 mitochondrial proteins in humans (approximately half of which are ubiquitously expressed in all tissues (1)), only 13 are encoded by the mitochondrial genome (mtDNA), all of which are subunits of the respiratory chain. In addition, 2 rRNAs and all 22 tRNAs are encoded by mtDNA. Mitochondria in *Saccharomyces cerevisiae* (herein referred to as “yeast”) contain roughly 1000 proteins per mitochondrion (2, 3). Except for respiratory complex I subunits, which are absent in yeast, and Var1p, a constituent of the small ribosomal subunit which is present in yeast (4), all mtDNA genes are conserved between yeast and humans.

Mitochondrial diseases affect at least 1 in 5000 (5), and as a result of their participation in numerous cellular processes, present with a range of clinical phenotypes.

Depending on which genome is affected, mitochondrial disease can follow maternal or mendelian inheritance (6–9). Because mtDNA only contains a few genes, the majority of pediatric cases of mitochondrial disease involve defects originating in the nuclear genome (7). This allows these diseases to be studied with all of the classic advantages of the yeast system such as the ability to combine relatively easy genetic manipulations with robust biochemical approaches that collectively facilitate detailed mechanistic studies. In addition,

yeast provides the added bonus of being amenable to suppressor screens and both large scale genetic and pharmacologic screens (for examples, see (10–13)).

Yeast also provide advantages specific to studying mitochondrial diseases, perhaps the most important of which is the ability to survive on fermentable carbon sources in the absence of mitochondrial function. Therefore, pathogenic mutations that lead to mitochondrial dysfunction are able to be maintained in yeast, so long as a fermentable carbon source is available. Furthermore, the growth phenotype provides a simple method of assessing mitochondrial function; when grown in media containing only non-fermentable carbon sources such as glycerol, ethanol, or lactate, strains exhibiting mitochondrial dysfunction are unable to grow.

A large number of diseases are associated with mtDNA defects, which are caused by point mutations, rearrangements, and/or deletions (14, 15). The utility of using yeast to model these diseases is exemplified by the unique ability to directly transform yeast mtDNA (16–18). In yeast, biolistic transformation of a *rho*⁰ strain (a strain completely lacking mtDNA) is able to generate the desired mutant strain relatively easily. This allows a defined mutation that may be identified in unrelated human patients to be studied in the context of one host nuclear genetic background. Of course, this capability additionally allows distinct mtDNA mutations in the same gene or different genes to be studied, compared and contrasted in the same genetic background.

In higher organisms, a limited number of mtDNA mutants have been described, most of which have been generated through indirect manipulation of mtDNA (19–21), although efficient complementation of a mtDNA deletion by targeting RNA to mitochondria has recently been described in mammalian tissue culture (22).

The difficulty in generating mutations in mammalian cells is compounded by their ability to harbor heteroplasmic mtDNA genomes. A single cell contains hundreds to thousands of individual mtDNA genomes. Normally all mtDNA copies are the same (termed “homoplasmy”), but when detrimental mutations are present, both wild type and mutant mtDNA genomes are present within the cell (termed “heteroplasmy”) (23, 24). Unlike mammalian cells, yeast become homoplasmic within a few generations (25, 26). In mammals, a mutation in mtDNA may be present in a few copies, but not result in a clinical phenotype because the remaining wild type mtDNA is able to complement the defect. It is not until the mutant mtDNA reaches a minimum critical number that dysfunction is evident. This phenomenon, known as the threshold effect, is often ascribed to the progressive and varied onset of mitochondrial diseases and pleiotropic phenotypes (24, 25). While this aspect cannot be modeled well in yeast, the absence of additional mutants or a subpopulation of wild type genes make yeast useful in studying pathogenic mtDNA mutants in isolation.

2.1. Yeast strains

A number of genetically distinct laboratory strains have been used to study mitochondrial functions. Some commonly used strains include S288c, W303, and D273. A more comprehensive list of yeast strains used in mitochondrial studies can be found in (27).

Strain S288c carries numerous mutations that affect mitochondrial function. The *MIP1* gene, which encodes for the mitochondrial DNA polymerase, contains an Ala to Thr substitution at the highly conserved residue 661 (termed the *MIP1*[S] allele). This increases the mutability of mtDNA, especially at elevated temperature (27, 28). S288c also contains a Ty1 element inserted into the 3' region of *HAP1* (29). Hap1p is a transcription factor that induces the expression of multiple oxygen-inducible genes, including some that are incorporated into respiratory complexes (30). The mutation greatly reduces the ability of Hap1p to induce

genes under the control of its upstream activation sequence (UAS), most notably *CYC1*, the gene encoding the mobile electron carrier, cytochrome *c* (29). Additionally, when the derivative of S288c, BY, was analyzed, it contained mutations in *SAL1* and *CAT5* (31). *SAL1* encodes the mitochondrial Mg-ATP/P_i exchanger, and *CAT5* encodes a protein required for ubiquinone (CoQ) biosynthesis. Thus, the S288c strain and its derivatives contain multiple mutations that result in less than optimal mitochondrial function. Despite this, S288c does have advantages; in addition to numerous auxotrophic markers, its genome has been completely sequenced, and the yeast knock-out collection was generated using the S288c derivative strains BY4741/2 (32).

W303 and its descendents do not contain mutations in *HAP1* (29), *SAL1*, or *CAT5*, leading to higher respiration rates than S288c. However, these strains do contain the *MIP1*[S] allele, increasing mtDNA mutability (28). Additionally, the presence of the *ade2* allele in combination with *MIP1*[S] can further increase mtDNA point mutability (27).

The D273 strain, commonly used due to its high respiratory rate, contains the wild type *MIP1* allele (28), although auxotrophic markers are limited, and the lack of the 2-micron episome prevents multi-copy plasmid transformation.

Therefore, the genetic background is an important consideration when using yeast to study mitochondrial processes. Wild type strains with decreased mitochondrial function may make the assessment of mutants with partial function more difficult. On the other hand, these strains may exacerbate certain phenotypes, making it easier to screen for suppressors or genetic interactions.

3. TRANSFER RNAS

The production of RNAs and proteins from mtDNA requires transcription and translation just like for the nuclear genome. For the most part, these processes are governed by genes encoded within the nuclear genome. Still, all 22 tRNAs required for mitochondrial protein synthesis are encoded by the mitochondrial genome. Mutations have been documented in each tRNA gene, and result in clinical phenotypes ranging from severe, such as MERFF (Myoclonic Epilepsy with Ragged Red Fibers), MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke), and Leigh syndrome, to relatively mild, such as diabetes and PEO (Progressive External Ophthalmoplegia; reviewed in (33), (14)). Worth considering, mutations in a single tRNA can impact the production of every mitochondrially encoded protein as long as their transcript contains a codon recognized by the mutant tRNA. Thus, patients harboring tRNA mutations often present with deficiencies in multiple/all of the OXPHOS complexes that incorporate mitochondrially encoded subunits (Complex I, III, IV, and V).

The ability to transform yeast mtDNA, and the conservation between yeast and human mitochondrial tRNAs, in particular tRNA^{Leu}, allows pathogenic tRNA mutations to be modeled in yeast (34–37). The conservation between yeast and human tRNAs is further demonstrated by the ability to rescue tRNA mutations in mammalian cells by transfection with wild type yeast tRNAs (38). Pathogenic mutants in yeast cause defective respiration, abnormal mitochondrial morphology, and mtDNA instability (35). Interestingly, the severity of the clinical phenotype correlates with the yeast phenotype. For instance, when a pathogenic mutation in tRNA^{Leu} (UUR) causing MELAS is modeled in yeast, a C to T mutation at nucleotide 26 (n.C26T), the strain shows severe growth defects in glycerol-containing media and an inability to respire. However, when a different mutation in tRNA^{Leu} (UUR), causing mitochondrial myopathy and chronic PEO, is modeled in yeast

(n.T20C), growth on glycerol and respiration is still defective compared to wild type, but not entirely absent (34).

Further validating yeast as a model, the molecular consequences of pathogenic mutations at conserved sites are the same in yeast as in humans. The n.A14G mutation in tRNA^{Leu} (UUR), equivalent to a mutation causing MELAS, displays an acylation defect, consistent with *in vitro* results of the mutant human tRNA (36, 39). Additionally, mammalian orthologs of yeast tRNA mutation genetic suppressors are also able to alleviate the phenotypes of mammalian cells harboring the mutations (35, 40–42).

Potentially, the yeast model of tRNA mutations can provide a definitive assay to distinguish between pathogenic mutations and neutral polymorphisms. Multiple different scoring systems have been described to predict if a patient's mutation will be pathogenic or silent (33, 43, 44) with varying degrees of success. The difficulty in this decision is due, in part, to differing degrees of heteroplasmy in different tissues of a patient, an inability to always survey all relevant tissues for degree of heteroplasmy (e.g. those impacted by a mutation), the fact that exceptions to the rules established by the scoring systems are known to exist, and the inability to follow the segregation of the mutation with the disease in small families (33). The presence or absence of a respiratory growth defect in a yeast strain with the equivalent mutation provides higher confidence in a mutation's ultimate classification as pathogenic or neutral.

4. MITOCHONDRIAL DNA STABILITY

4.1. DNA polymerase

The mitochondrial genome is replicated by DNA polymerase gamma. The holoenzyme forms a heterotrimer (45), and is comprised of a catalytic subunit encoded by the nuclear gene *POLG*, and two accessory subunits encoded by the nuclear gene *POLG2*. The yeast ortholog, Mip1p, shares 43% identity with *POLG* (46, 47). However, in contrast to mammalian *POLG*, Mip1p is not thought to bind any accessory subunits. The linker region that binds the accessory subunits is poorly conserved between Mip1p and *POLG*. In contrast, the identity in the polymerase and exonuclease domains of Mip1p and *POLG* approaches 65%.

Mutations in *POLG* cause PEO, Alpers' syndrome, and ataxia-neuropathy syndrome (48). All three diseases are caused by increases in mtDNA depletion, large scale deletions, and/or point mutations that result in impaired mitochondrial function and ultimately cell death. Over 150 disease associated mutations in *POLG* have been documented, and are compiled at the Human DNA Polymerase Gamma Mutation Database (<http://tools.niehs.nih.gov/polg/>).

In yeast, the mechanistic defect of mutant Mip1p is relatively easy to resolve. Defects in mtDNA replication that cause depletion or large scale deletions result in a cytoplasmic *petite* phenotype. *Petite* colonies can be identified by their inability to form large colonies on fermentable media (*petite* colonies are unable to survive on non-fermentable carbon sources), and the frequency of *petite* colony formation is easy to ascertain in *MIP1* mutants. Defects in mtDNA replication can result in *rho*⁰ or *rho*⁻ (partial loss of mtDNA, but inability to respire) phenotypes. This can be further resolved by crossing the *petite* strain with *mit*⁻ strains that harbor point mutations in mitochondrially encoded subunits of respiratory complexes III (*cob*) and IV (*cox2* or *cox3*). *Rho*⁰ colonies will be unable to complement the *mit*⁻ strains, while the *petite* phenotype will be rescued after crossing *rho*⁻ and *mit*⁻ strains as long as the lesion in the *rho*⁻ strain is not the same as the *mit*⁻ strain. Alternatively, Southern blotting with a mtDNA specific probe or DAPI staining can indicate the presence of mtDNA. *MIP1* mutations that increase the frequency of point mutations are

commonly assessed by the strain's ability to grow in the presence of erythromycin. Erythromycin inhibits mitochondrial protein synthesis, but point mutations in the mitochondrial 21S rRNA gene confer resistance. Therefore, *MIP1* mutations that result in an increased frequency of erythromycin resistance indicate an increase in point mutability (49).

The ability to model pathogenic *POLG* mutations in Mip1p has many advantages. Many patients carry multiple pathogenic mutations, both in *cis* and *trans*, as well as non-pathogenic single nucleotide polymorphisms (SNPs). In addition, limited family histories of patients make the mode of inheritance difficult to resolve. By modeling individual mutations in *MIP1*, disease-causing mutations can be distinguished from harmless SNPs. Once a pathogenic mutation is positively identified, dominant or recessive mechanisms can be determined by expressing the mutant in either haploid *deltamip1* or diploid cells containing one copy of wild type *MIP1*. For example, modeling the pathogenic human mutation G1076V (all missense mutations discussed in this review list the normal amino acid first followed by the amino acid position in the human or yeast protein and finally the identity of the mutant residue) in a haploid *deltamip1* yeast strain results in 100% *petite* colony formation, indicating that the mutation causes Mip1p dysfunction. When the same mutant Mip1p is heteroallelically expressed with wild type Mip1p, the frequency of *petite* colony formation is reduced to 1.7%; thus the G1076V functions as a recessive mutation. In contrast, the dominant pathogenic R853Q mutation results in 88% and 100% *petite* colony formation frequency when modeled in a diploid strain containing one wild type Mip1p and a haploid *deltamip1* strain, respectively (50).

Finally, yeast models allow for screens of potentially therapeutic suppressors. For instance, growth of Mip1p mutants on media containing reactive oxygen species (ROS) scavengers partially suppresses mtDNA damage (51), indicating that ROS damage contributes to mtDNA instability. ROS alone are able to induce mtDNA damage and depletions (52). Mutations in mtDNA caused by Mip1p mutants may cause respiratory complex dysfunction, which leads to the production of more ROS, creating a detrimental positive feedback loop.

A subset of *POLG* mutations occur at residues important for nucleotide binding and selectivity. When these mutants are modeled in Mip1p, the *petite* phenotype is suppressed by overexpression of Rnr1p, the yeast ribonucleotide reductase; or deletion of Sml1p, an Rnr1p inhibitor. In both cases, the mitochondrial dNTP pool is increased allowing suppression of this class of Mip1p mutant (51).

The large number of modeled mutations allow for a generalization of the conclusions, which in turn will aid in predicting the effect of novel mutations. Most *POLG* mutations are found in the polymerase domain. Recessive polymerase domain mutants could cause the polypeptide to be unstable, or unable to bind mtDNA. Dominant polymerase domain mutants could have defects in processivity, whereby they bind DNA but are unable to replicate it, and as a result inhibit the wild type Mip1p either directly or indirectly. Some dominant mutations resulting in low processivity also display an increase in point mutability. This is thought to occur by increasing the exposure of single stranded DNA, thereby increasing the susceptibility of the template to mutagenic lesions, such as those generated by ROS. For example, the Mip1p mutants T654A and R656Q increase both *petite* colony formation frequency and point mutagenesis (50). Most mutations in the exonuclease domain are less pathogenic, and result in increased point mutability rather than mtDNA depletion, with a few notable exceptions (53). To date, no disease-associated *POLG* mutation has demonstrated a total lack of exonuclease activity. In fact, the mtDNA mutation frequency when pathogenic mutations are modeled in the exonuclease domain is only 12% of that observed when the exonuclease domain is absent altogether (50).

Similar to the modeled tRNA mutants, a good correlation has been noted between the severity of disease and the degree of mtDNA maintenance. That is, mutations in patients with an earlier age of onset and more severe clinical phenotypes display higher frequencies of *petite* colony formation in the yeast model (53–55).

4.2. Adenine nucleotide translocase

The adenine nucleotide translocase (ANT) is the most abundant protein in the inner membrane and mediates the 1:1 exchange of ATP and ADP across the membrane, representing the terminal step in oxidative phosphorylation. The directionality of nucleotide transport by ANT is not inherent however, and productive transport (ATP_{out}, ADP_{in}) is driven by the membrane potential. Thus, under experimental conditions where the membrane potential is altered, ANT can preferentially undergo non-productive transport (ADP exchanged for ADP, or ATP exchanged for ATP) or counter-productive transport (ATP_{in}, ADP_{out}) (56). ANTs have long been thought to function as homo-dimers (57–59), although this has recently been challenged and a monomeric functional unit proposed (60–62).

There are four ANT isoforms in humans (63–65). ANT1 is expressed primarily in heart and skeletal muscle (66), and is 50% similar to the yeast ortholog, Aac2p (for ADP/ATP carrier) (67). Although three AAC isoforms are present in yeast, only Aac2p is required for respiratory growth (68).

Six ANT1 mutations have been described in patients, five of which present with autosomal dominant PEO and mtDNA depletion (69–74). The other ANT1 mutant, A123D, is recessive, and causes hypertrophic cardiomyopathy, mild myopathy with exercise intolerance, lactic acidosis, and large-scale mtDNA deletion in skeletal muscle (74). Worth briefly considering is that the phenotypes associated with ANT1 mutations are surprisingly mild given the critical role of ANT in OXPHOS. The most likely explanation for this is the existence of multiple ANT isoforms with overlapping functions and expression patterns. Five of the six pathogenic ANT1 mutations occur in regions highly conserved between the yeast and human proteins.

When the conserved pathogenic mutations are modeled in yeast Aac2p and then expressed in a strain lacking endogenous Aac2p, the mutant strains display reduced growth on respiratory media (71, 74, 75), and reduced cytochrome *b* and *aa₃* spectra, indicating a reduction in assembled respiratory complexes III (cytochrome *b*) and IV (cytochrome *aa₃*). Interestingly, when the M114P, A128P, or A137D Aac2p mutants (equivalent to L98P, A114P, and A123D ANT1 mutants) are introduced into a $\Delta aac1\Delta aac2$ strain, cytochromes *b* and *aa₃* are reduced more than the null mutant alone (74, 75). Consistent with the reduced cytochrome spectra, the A128P, M114P, and S303M (equivalent to the V289M ANT1 mutation) mutants show a decrease in complex IV (COX) activity and respiration (75). It is currently unknown if the decrease in cytochrome content and respiratory complex activity is a direct result of mtDNA instability, or some other effect caused by the Aac2p mutations.

While the A137D Aac2p mutant exhibits no nucleotide transport activity (74), the A128P, M114P, and S303M mutants display altered transport kinetics such that ATP was preferred over ADP (75). One potential consequence of ATP/ATP homoexchange over productive heteroexchange is a resultant decrease in the intramitochondrial ADP concentration. This could explain the decrease in respiration efficiency, since respiratory complexes IV and V can be allosterically regulated by ADP (76, 77). This may also affect the dNTP pool, preventing accurate mtDNA replication (71).

The A128P, M114P and S303M Aac2p mutants, when expressed in heteroallelic strains together with wild type Aac2p, exhibited normal oxidative growth phenotypes, indicating that these phenotypes are recessive. However, the cytochrome *b* and *aa₃* profiles are reduced when Aac2p harbor the A128P or M114P mutations and mtDNA mutability increases for A128P and S303M Aac2p mutants, demonstrating dominant phenotypes. Interestingly, mtDNA mutability is not affected in M114P and the cytochrome spectra is reduced in S303M, indicating that these phenotypes may arise through independent mechanisms (75).

Consistent with a gain of function dominant phenotype, A106D (equivalent to the A90D ANT1 mutation), A128P, M114P, and A137D Aac2p mutants result in an increased frequency of *petite* colony formation when overexpressed. As the number of A137D alleles increases, the total amount of mtDNA, as well as the mtDNA-encoded Cox2p, decreases. When these mutants are expressed (or overexpressed) in a diploid strain with a wild type copy of AAC2, in the presence of the ionophore carbonyl cyanide *m*-chlorophenyl hydrazone (CCCP) or absence of Yme1p (both are conditions which decrease the mitochondrial membrane potential), the cells are not viable on glucose media. The authors suggest that overexpression of the pathogenic Aac2p mutants induces an unregulated ion channel, decreasing the membrane potential, although this was not directly tested and may instead be the result of altered nucleotide transport modes (75). The observed decrease in mitochondrial membrane potential for Aac2p mutants, in combination with the presence of CCCP or absence of Yme1p, may reduce the membrane potential below the threshold required for viability (78). Consistent with this, respiratory control ratio values, a quantitative measure of respiratory coupling, are decreased in the heteroallelic Aac2p mutant strains (78). Strikingly, when the mutant A128P Aac2p is overexpressed, the mitochondrial membrane potential is lower than wild type Aac2p in the presence of CCCP (79). The decrease in membrane potential that results from pathogenic Aac2p mutations would likely decrease the import of nuclear encoded proteins into the mitochondrial matrix, including those involved in mtDNA maintenance and replication. However, the contribution of a reduced membrane potential caused by ANT1 mutants to the associated human disease has yet to be determined. Worth considering is that yeast with no Aac2p function are *petite* negative (80), that is, loss of Aac2p function in *rho*⁰ yeast is lethal. *Rho*⁰ yeast lack functional respiratory complexes capable of generating a membrane potential. The mitochondrial membrane potential is required for the import of the vast majority of mitochondrial proteins encoded in the nucleus, and thus for viability. In *rho*⁰ yeast, a minimal membrane potential sufficient for mitochondrial biogenesis is maintained by Aac2p by the electrogenic exchange of ATP into and ADP out of the mitochondrial matrix (81). Therefore, mutations that affect Aac2p transport activity would cause the mitochondria to become especially sensitive to additional mtDNA defects.

4.3. Stress inducible yeast MPV17 homolog

MPV17 was first identified in a transgenic mouse containing a proviral insertion that disrupted its expression, causing severe renal failure (82). Originally thought to be localized to peroxisomes (83), the yeast ortholog, Sym1p (stress-inducible yeast MPV17) was shown to reside in the mitochondrial inner membrane (84). *Deltasym1* yeast are unable to grow on ethanol at elevated temperature. This phenotype can be rescued with human MPV17, indicating functional conservation between the yeast and human protein (84).

While the function of MPV17 is still unknown, patients with *MPV17* mutations exhibit mtDNA depletion in the liver, which leads to organ failure. Phenotypes can range from severe hepatopathy causing early death, to moderate liver dysfunction, and can be accompanied by polyneuropathy, leukodystrophy, progressive spinocerebellar ataxia,

hypoparathyroidism, tubulopathy, intestinal dysmotility, and pigmentary retinopathy (85–89).

Of the seven *MPV17* mutations described in patients, three are missense mutations. Two families carried homozygous mutations R50Q and N116K; and the third carried a heterozygous R50W mutation with a 25 base pair deletion in the other *MPV17* allele, resulting in a predicted truncated protein (85). When the pathogenic mutations are introduced into Sym1p, neither N172K (equivalent to the N116K *MPV17* mutant) nor R51W (= R50W *MPV17* mutant) is able to rescue the *deltasym1* phenotype, whereas R51Q (= R50Q *MPV17* mutant) can partially rescue *deltasym1*. All three mutants display an increase in *petite* colony formation. The *petite* frequency of R51W and N172K is similar to *deltasym1*, whereas the *petite* frequency of R51Q is approximately 50% of *deltasym1*. Southern blot analyses indicate that all three mutants contain large scale mtDNA rearrangements, consistent with the phenotype of patients and the *mpv17*^{-/-} mouse (90).

Although both the yeast model and patient phenotypes indicate that *SYM1/MPV17* mutations result in mtDNA depletion, the link between Sym1p function and mtDNA maintenance remains enigmatic. *SYM1* was first identified as being upregulated during heat shock, and in playing a role in ethanol metabolism or tolerance (84). One study demonstrated that at elevated temperature, *deltasym1* yeast are unable to grow on ethanol but grow like wild type strains on glycerol, ethanol/glycerol, acetate, and to a lesser extent acetaldehyde, leading the authors to conclude that the absence of *SYM1* does not result in a general respiratory defect (84). However, a later study showed that *deltasym1* growth is reduced on ethanol, glycerol, or acetate, as well as lactate or 0.1% glucose (91). The reason behind these discrepant results is not immediately clear as both studies employed the same parental yeast strain.

Deltasym1 yeast also display mitochondrial swelling, flattened cristae, and the accumulation of electron dense particles, consistent with the phenotype of the *mpv17*^{-/-} mouse (90), implying that Sym1p function is necessary to maintain normal mitochondrial morphology (91). However, it has been noted that the absence of mtDNA causes altered mitochondrial morphology (92) and that mutations causing altered mitochondrial morphology eventually lead to mtDNA loss ((93, 94), reviewed in (95)). The causality between mtDNA depletion and altered mitochondrial morphology in the absence of Sym1p function has yet to be established.

The *deltasym1* phenotype is exacerbated in the absence of *ODC1*, *YMC1*, or either citrate carrier *CIT1* or *CIT2* (91). Ymc1p and Odc1p are mitochondrial carriers that transport tricarboxylic acid cycle (TCA) intermediates (96, 97). When TCA enzyme activity is analyzed, succinate dehydrogenase (SDH) activity is reduced by approximately 60% in the *deltasym1* yeast (91). Interestingly, a fraction of *MPV17* patients also exhibit SDH defects in the liver (85, 88, 89).

The *deltasym1* phenotype can be suppressed by overexpression of Ymc1p and Odc1p; or by supplementing the media with glutamate, glutamine, aspartate, or asparagine, amino acids that can be metabolized and enter the TCA cycle as alpha-ketoglutarate or oxaloacetate (91). This indicates that the *deltasym1* phenotype can be alleviated by increasing the pool of TCA cycle intermediates. Ymc1p overexpression reduces the frequency of *petite* colony formation below that of the wild type strain, while Odc1p overexpression reduces *petite* colony formation to approximately 53% of *deltasym1*. Interestingly, *petite* colony formation is also decreased when Odc2p is overexpressed, but Odc2p is unable to rescue the growth phenotype, indicating that the *deltasym1* growth defect and mtDNA depletion are caused independently (91).

Consistent with the link between Sym1p and the TCA cycle is the observation that *deltasym1* yeast have reduced glycogen storage (91). Glycogen synthesis requires gluconeogenesis, which is regulated by the flux of TCA cycle intermediates. Defects in glycogen storage may explain the hypoglycemic crises suffered by patients with *MPV17* mutations (85, 98).

Despite the information provided by the yeast model, more work must be done to elucidate the molecular function of MPV17/Sym1p, and how mutations lead to mtDNA depletion. Unfortunately, the abundance of TCA cycle intermediates in *deltasym1* yeast has not been reported. Such metabolomic data may help to distinguish between Sym1p being directly involved in the regulation of the TCA cycle, and thus its absence resulting in altered metabolite levels; or in glycogen synthesis, where increasing the level of TCA intermediates above the normal range is sufficient to suppress the mutation. Additionally, the pathogenic missense mutations were only shown to affect growth on ethanol at elevated temperature and *petite* colony formation. It will be interesting to learn if the yeast strains harboring mutant Sym1p mimic the other phenotypes of the *deltasym1* strain.

5. MITOCHONDRIAL PROTEIN IMPORT

While mitochondria contain between 1000 and 1500 different proteins (1–3, 99), only about 1% are encoded by mtDNA. Therefore, most mitochondrial proteins must not only be targeted to mitochondria, but also sorted to the correct submitochondrial compartment (for a comprehensive review, see (100)). After synthesis on cytosolic ribosomes, virtually all preproteins are recognized by the Translocase of the Outer Membrane (TOM) complex, which facilitates movement across the outer membrane (OM). OM beta-barrel proteins are inserted by the Sorting and Assembly Machinery (SAM) complex, while proteins with alpha-helical transmembrane domains require Mim1p for their insertion into the membrane (101, 102). Insertion into the inner membrane (IM) or translocation into the matrix invariably requires the proton-motive force generated by the electron transport chain. Polytopic IM proteins with internal sorting signals are inserted into the IM by the Translocase of the Inner Membrane (TIM) 22 complex. Notably, external ATP is not needed for this process. Substrates of the TIM22 translocon include members of the mitochondrial carrier family as well as Tim23p and Tim22p of the TIM23 and TIM22 translocons, respectively. The TIM23 complex utilizes the mitochondrial membrane potential $\pm$ ATP to deliver precursors containing N-terminal targeting signals to three distinct compartments: the matrix, the IM, and the intermembrane space (IMS). Import into the matrix is distinguished from release into the IM or IMS by additionally requiring ATP to fuel the Presequence translocase-Associated Motor, or PAM complex. For those precursors that contain a hydrophobic “stop-transfer” signal, the N-terminal targeting sequence is removed by the matrix processing peptidase followed by either the lateral release into the IM or, subsequent to further processing by additional proteases that remove the “stop-transfer” signal, release into the IMS.

5.1. Disulfide relay system

Another pathway for the import of soluble IMS resident proteins is the recently discovered disulfide relay system (reviewed in (100, 103–106)). Substrates of the disulfide relay system are characterized by their small size, lack of N-terminal targeting signal, and conserved cysteine residues. The cysteine residues are required for disulfide bond formation between the substrate and import machinery, and for proper protein folding. The IMS-resident receptor, oxidized Mia40p, forms a disulfide intermediate with incoming preproteins. Protein substrates are then released from Mia40p, leaving it in a reduced state. The FAD-dependent sulfhydryl oxidase Erv1p, re-oxidizes Mia40p, allowing another substrate to bind. Finally, Erv1p reduces cytochrome *c* allowing the re-oxidized Erv1p to participate in

another round of import. Thus, this pathway mediates the proper folding of soluble proteins that contain disulfide bonds, indicating that the IMS is not contiguous with the cytosol with regards to its redox chemistry as previously thought. The proper folding of substrates of this pathway is postulated to prevent their retrograde translocation through the TOM complex back into the cytosol via a folding trap mechanism. Lastly, it is worth mentioning that reduced cytochrome *c* donates its electron to complex IV and finally O₂. As such, the disulfide relay system contributes, albeit to a minor extent, to the ultimate generation of the membrane potential across the IM.

The human homolog to *ERV1* is *GFER*. Recently, a Moroccan family presenting with congenital cataracts, progressive muscular hypotonia, sensorineural hearing loss, and developmental delay was identified with a mutation in *GFER*, R194H (107). Ultrastructural analyses of patient skeletal muscles demonstrated altered mitochondrial morphology, with thickened, electron dense cristae, and a subset of mitochondria with abnormal IMS morphology. Multiple mtDNA deletions were present.

When the pathogenic R194H mutation is modeled in yeast *Erv1p* (R182H), growth is normal on fermentative and respiratory media. However, *Erv1p* R182H does not support growth at elevated temperature. Cytochrome *aa₃*, but not *b* or *c*, is reduced, and cytochrome oxidase (COX or complex IV) activity is correspondingly reduced by 45%, suggesting that complex IV subunits or assembly factors are not efficiently imported. The frequency of *petite* colony formation in the mutant also doubled compared to the wild type controls (107).

Confirmed and predicted substrates of the disulfide relay system include several COX assembly factors (104, 105), which help to explain the specific cytochrome *aa₃* reduction and decreased COX activity. Other substrates include Mdm35p and small Tim proteins which may cause abnormal mitochondrial morphology and mtDNA destabilization either directly or indirectly when they are not imported properly. Thus, the phenotypes observed in the patients likely result from the defective import of substrates of the disulfide relay system which was first identified and subsequently molecularly characterized in yeast (108–124).

5.2. Small Tim proteins

The small Tim proteins (in yeast Tim8p, Tim9p, Tim10p, Tim12p, and Tim13p) are structurally related IMS proteins which assemble into soluble hetero-oligomeric complexes (except for Tim12p), and contain twin CXXXC motifs that are required for import and folding (all of the small Tims). The small Tim proteins are canonical substrates of the aforementioned disulfide relay system. The assembled hexameric small TIM complexes (125) function to deliver hydrophobic polytopic membrane proteins from the TOM complex across the aqueous IMS to the TIM22 translocon which integrates such proteins into the IM (126–131). Tim9p assembles with Tim10p and Tim8p assembles with Tim13p. The Tim9/Tim10 complex is the major chaperone for substrates of the TIM22 pathway across the IMS. In addition, a separate pool of Tim9p and Tim10p, together with Tim12p, are stably associated with the TIM22 translocon (128). While both Tim9p and Tim10p are essential for yeast viability, yeast can survive in the absence of Tim8p and/or Tim 13p. To date, the only known substrate of the Tim8/Tim13 complex is the pore-forming subunit of the TIM23 translocon, Tim23p (129, 132, 133). Tim8p, and its human homolog, deafness dystonia peptide 1 (DDP1), were identified by sequence similarity to the other small Tim proteins in yeast (134). Functional conservation is demonstrated by *deltatim8deltatim13* yeast that co-express DDP1 and human TIM13. Mitochondria isolated from this strain are able to import both human and yeast Tim23p (135, 136).

Mutations in the human deafness dystonia peptide 1, *DDP1*, result in Mohr-Tranebjaerg syndrome. Patients present with sensorineural hearing loss, dystonia, mental retardation, and

blindness. Most of the documented mutations result in a truncated protein due to frameshift mutations or premature stop codons (137–140), with the exception of one intronic mutation predicted to alter splicing (141) and two missense mutations, C66W (142) and M1I (143). All of the mutations result in a complete loss of DDP1 function.

TIM8 is not essential for viability (134), but the *deltatim8deltatim13* strain is not viable at low temperature (133), providing a simple assay to test for Tim8p function in pathogenic mutants (144). The Tim8/Tim13 complex is especially required when the mitochondrial membrane potential is low (133), presumably to retain imported peptides in the IMS and prevent retrograde translocation back to the cytoplasm.

The pathogenic DDP1 mutation C66W occurs within the CXXXXC motif. When this mutation is modeled in Tim8p, it cannot form a complex with Tim13p, despite proper mitochondrial localization (135, 144). In addition to an inability to fold properly, the mutation may also prevent proper handling by the disulfide relay system, thus providing another possible molecular explanation for the loss of function of this DDP1 mutation.

6. MITOCHONDRIAL DYNAMICS

Mitochondria are not static organelles; instead they form an elongated network that continually fuses, divides, and moves throughout the cell. Mitochondrial fusion allows mixing of proteins and mtDNA between individual mitochondrion, minimizing the effect of ROS-mediated mutations and allowing gene complementation (reviewed in (145, 146)). Mitochondrial fission, on the other hand, is important for segregation of dysfunctional mitochondria which will be eliminated by mitophagy (147), and plays a role in apoptosis (reviewed in (148)). Disruptions in the balance of these two opposing processes lead to mitochondrial dysfunction.

6.1. Fusion

6.1.1. Outer membrane fusion—In mammals, fusion of the outer membrane requires two genes: *MFN1* and *MFN2*. *MFN1* and *MFN2* are GTPases that tether adjacent membranes (149, 150) and mediate fusion. *MFN1* and *MFN2* can form homo- or hetero-oligomeric complexes via their heptad repeat region (150). Null mutations in either *MFN1* or *MFN2* are embryonic lethal in mice (151). However, only when both *MFNs* are disrupted in mouse embryonic fibroblasts (MEFs) is fusion completely abolished resulting in reduced growth, mitochondrial membrane potential, and respiration (151). Null mutations in only one *MFN* in MEFs results in greatly reduced mitochondrial fusion, but no major cellular dysfunction (151). As a result, distinct functions for each *MFN* have been postulated (149, 152). When Charcot-Marie-Tooth disease type 2A mutant *MFN2* is expressed in MEFs, wild type *MFN1* but not wild type *MFN2* is able to rescue fusion (153), highlighting the functional importance of *MFN1/MFN2* hetero-oligomers. Yeast contain only one *MFN* homolog, *Fzo1p*. Studies in yeast have been instrumental in determining the mechanism of mitochondrial outer membrane fusion (154, 155).

Mutations in *MFN2* result in the autosomal dominant Charcot-Marie-Tooth disease type 2A (CMT2A) (156). Patients with *MFN2* mutations present with axonal degeneration of peripheral nerves and muscle weakness, although the age of onset and severity is variable (reviewed in (157)). Approximately 60 mutations in *MFN2* have been found in patients with CMT2A (158), most of which occur in or near the GTPase domain. Since wild type *MFN1* can complement mutated *MFN2* (153), it is suggested that tissues with lower *MFN1* expression are more sensitive to *MFN2* mutations.

Modeling CMT2A mutations in yeast Fzo1p have had mixed results. For example, the pathogenic mutant I213T, when modeled in Fzo1p, results in a complete loss of function. Mitochondria are fragmented and aggregated, and no GTPase activity is detected (159). However, when the CMT2A mutation T105M is modeled in yeast, mitochondria remain tubular, but with slightly altered morphology and poor distribution. Mitochondria retain the ability to fuse, and no respiratory growth defect is observed (159). In contrast, the MFN2 T105M mutant results in no mitochondrial fusion when expressed in *mfn1^{-/-} mfn2^{-/-}* MEFs (153). Similarly, no fusion defect is observed when the pathogenic CMT2A mutation L734V is modeled in yeast. In addition, the dominant negative phenotype of MFN2 mutations in CMT2A is not recapitulated in the yeast model (159). The inability of the yeast model to fully recapitulate the phenotype of patient mutations may reveal fundamental differences in OM fusion between yeast and mammals.

6.1.2. Inner membrane fusion—Fusion of the IM is mediated by OPA1 in mammals, and by its ortholog Mgm1p in yeast (160). Mgm1p is a dynamin-related GTPase that self assembles and tethers adjacent inner membranes, bringing them into close physical proximity for fusion (161). Like other dynamin family proteins, OPA1/Mgm1p contain a conserved GTPase domain, a middle domain, and an assembly or GTPase effector domain (GED) (162). The middle and GED domains are thought to promote self-assembly into spiral-like structures that stimulate GTPase activity (163). Similar to Fzo1p mutations, mitochondria in *mgm1* deficient yeast are unable to fuse (164, 165), leading to fragmented mitochondria. However, the fragmentation phenotype can be rescued by disrupting the mitochondrial fission gene, *dnm1* (164, 166).

There are multiple OPA1 isoforms that are generated as a result of alternative splicing and limited proteolysis by the *m*-AAA and *i*-AAA proteases (167–171). The proper balance of the numerous OPA1 isoforms is critical for IM fusion. This is illustrated by the fact that OPA1 is subject to an inducible cleavage event, mediated by the metalloprotease OMA1, which is stimulated upon dissipation of the mitochondrial membrane potential and results in the selective removal of the long OPA1 isoform, thus preventing IM fusion (168, 172, 173). Dissipation of the membrane potential signals mitochondrial dysfunction and prevents fusion of damaged mitochondria with healthy mitochondria. In yeast, only two Mgm1p isoforms are present, a long (l-Mgm1p) and short (s-Mgm1p) isoform, which are present in roughly equal amounts. The short isoform is generated through cleavage by the rhomboid protease, Pcp1p (174, 175). Both isoforms are required for competent fusion and mitochondrial morphology maintenance (174). l-Mgm1p is anchored to the IM through its N-terminal domain, while s-Mgm1p is thought to be a soluble IMS protein. During fusion both isoforms associate to form heteromeric complexes, either in the same or in an adjacent membrane, to facilitate IM fusion (176, 177).

OPA1 is mutated in optic atrophy type 1, a dominant optic neuropathy. Patients present with progressive loss of visual acuity, optic nerve pallor, and abnormalities in color vision. These symptoms are suggested to be the result of retinal ganglion cell degeneration, which leads to optic nerve atrophy (178). Patients also exhibit altered mitochondrial morphology (160). Over 200 *OPA1* mutations have been documented (179), most of which are predicted to lead to OPA1 loss of function, either by truncation or mutations in the GTPase domain that render OPA1 catalytically inactive. Additionally, some patient cells harboring *OPA1* mutations exhibit increased OPA1 processing, leading to extensive mitochondrial fragmentation (168), a phenotype that highlights the importance of a proper balance of OPA1 isoforms for IM fusion.

Mgm1p mutations in the GTPase or GED domains are unable to rescue *deltamgm1* yeast (164, 166). Expression of mutant Mgm1p in the presence of wild type Mgm1p retains the

fusion defect, which is exacerbated as the copy number of the mutant Mgm1p increases (166). This potentially provides a mechanism for the dominant inheritance of optic atrophy type 1. Any mutation that disrupts the function of the GTPase domain would assemble into oligomers with wild type Mgm1p and prevent proper mitochondrial fusion. Truncation mutants may exhibit dominant inheritance through haploinsufficiency, since the middle and GED domains required for oligomerization are located on the C-terminus (162, 166).

In yeast lacking *mgm1*, ATP synthase assembly is disrupted due to a decreased abundance of Tim11p/subunit e (180), which is required for ATP synthase multimerization (181). Additionally, cristae formation is altered, and cytochrome *c* levels are reduced (180). As oligomers of the ATP synthase are required to maintain normal cristae morphology (182–184), the reduced abundance of subunit e in the absence of Mgm1p may contribute to the altered cristae morphology. The loss of cytochrome *c*, which is also seen in *OPA1* mutants, could lead to increased levels of apoptosis, providing another potential mechanism of pathogenesis. Another possibility is that mitochondrial fusion enables protein complementation and mtDNA repair, consistent with the fact that loss of fusion leads to mtDNA depletion (185).

Defects in the mitochondrial fusion machinery also affect mitochondrial movements (186), which may help explain why neurons, which require mitochondria to traverse large distances from cell body to synapse, are most affected in mitochondrial fusion diseases (185, 187).

6.2. Fission

Mitochondrial fission is mediated by another dynamin-related protein, DRP1 in humans (188), and its homolog Dnm1p in yeast (189). Dnm1p is a GTPase that localizes to sites of mitochondrial fission (190), oligomerizes (191) and constricts membranes in a similar manner to dynamin (192). Interestingly, one difference between dynamin spirals and Dnm1p spirals is their size. The oligomeric Dnm1p spirals are larger than those formed by dynamin to accommodate the larger and more variable size of mitochondria compared to endocytic vesicles (192, 193). In the absence of DRP1/Dnm1p, mitochondria form elongated, highly branched networks due to continuing and unopposed mitochondrial fusion (189, 190).

In contrast to the numerous pathogenic mutations in proteins involved with mitochondrial fusion, to date only one pathogenic mitochondrial fission mutant has been reported. The patient showed abnormal brain development, abnormal gyral pattern and dysmyelination, optic atrophy, hypotonia, and elevated lactate levels. The patient died at 37 days. Despite the elevated lactate levels, which indicate respiratory chain dysfunction, histochemical analysis did not indicate a respiratory defect (194). A point mutation, A395D, was found in the middle domain of DRP1.

Middle domain mutants in Dnm1p had been previously shown to prevent oligomerization and consequently decrease GTP hydrolysis (195, 196). As such, the pathogenic DRP1 mutation as well as other middle domain mutations were shown by yeast two-hybrid to self-assemble into tetramers, the basic building block of DRP1/Dnm1p, but fail to form higher order oligomers. *In vitro* assays demonstrate that these mutants have decreased GTPase activity (197), consistent with studies in yeast that show an increase in GTP hydrolysis as Dnm1p assembles into higher order oligomers (193).

In *deltadnm1* yeast, mitochondria are still inherited by daughter cells normally and retain membrane potential, respiratory growth capacity, and proper protein import, despite displaying abnormal morphology (189). It is unclear how a mutation that does not appear to cause major mitochondrial dysfunction in yeast is able to translate into such a devastating phenotype in humans, although one possibility is through impaired mitophagy.

Mitophagy is the removal of mitochondria via macroautophagy, and facilitates both the reduction of mitochondrial numbers during decreased metabolic demand and the targeted removal of dysfunctional mitochondria (198). The stark difference in phenotype between the *DRP1* mutant patient and *deltadnm1* yeast could be the result of high mitochondrial demand in neurons and lower demand for yeast grown in glucose-containing media.

7. MITOCHONDRIAL PROTEASES

The mitochondrial inner membrane possesses two metalloproteases that belong to the AAA (ATPase Associated with various cellular Activities) family of P-loop ATPases. The *i*-AAA protease is a homo-oligomeric complex that protrudes into the IMS, whereas the *m*-AAA protease faces the matrix. The *m*-AAA protease in yeast is strictly hetero-oligomeric, composed of the subunits Yta10p and Yta12p. In contrast, the mammalian *m*-AAA protease can assemble as hetero-oligomers and depending on the subunit, additionally into homo-oligomers (199). These proteases degrade non-assembled or misfolded subunits of respiratory complexes, and process premature peptides to their mature forms (for review, see (200)). As such, these proteases are critical components of the quality control apparatus of the mitochondrial IM.

The *m*-AAA protease in humans is encoded by *SPG7* (*PARAPLEGIN*) and *AFG3L2* (mice contain a 3rd gene, *AFG3L1* that is a pseudogene in humans). The yeast homologs are *YTA10* and *YTA12*. Expression of *AFG3L2* and *SPG7* in a *deltayta10deltayta12* yeast strain is able to restore protease activity demonstrating both functional conservation and that yeast substrates are recognized by the mammalian proteins. Intersubunit complementation is also possible; an *m*-AAA protease consisting of a Yta10p with a mutated ATPase domain and a Yta12p harboring a mutated protease domain retains proteolytic activity (201, 202). Among the substrates of the *m*-AAA protease are MrpL32p, a nuclear-encoded mitochondrial ribosome subunit; and Cox1p and Cobp, mitochondrially encoded subunits of respiratory complexes IV and III, respectively. In the absence of *m*-AAA protease function OXPHOS is impaired due to unassembled respiratory complexes (203–205), a consequence of impaired ribosome assembly due to the defect in MrpL32p processing and biogenesis (206). This provides an easy screening method in the yeast model; if a mutation in an *m*-AAA protease subunit ablates function, the complemented strain will be unable to grow on non-fermentative carbon sources.

Hereditary spastic paraplegia (HSP) is a group of heterogeneous neurodegenerative disorders characterized by progressive weakness and spasticity of the lower limbs (207, 208). One cause of HSP is a non-functional *SPG7*. Patients exhibit degeneration of axons, but not neuronal cell bodies, in corticospinal tracts, dorsal columns, and spinocerebellar fibers. Skeletal muscle biopsies show ragged red fibers (indicative of mitochondrial proliferation) and COX deficiency (209). The yeast model has been used to distinguish pathogenic mutations from silent polymorphisms in patient gene sequences. By co-expressing the mutated *SPG7* gene with a non-functional *AFG3L2* in a *deltayta10deltayta12* yeast strain, impairment of proteolytic activity can be easily inferred by the strain's ability to grow on respiratory substrates (202).

The other subunit of the *m*-AAA protease, *AFG3L2*, has recently also been implicated in human disease. *AFG3L2* is one of the 28 known loci that cause autosomal dominant spinocerebellar ataxias; neurological disorders characterized by imbalance, progressive gait and limb ataxia, and dysarthria that results from Purkinje cell degeneration (210, 211). Like pathogenic *SPG7* mutations, *AFG3L2* mutations disrupt *m*-AAA proteolytic activity and cause a defect in COX activity. Unlike *SPG7*, *AFG3L2* is able to form functional homo-oligomers. Thus, whereas in the absence of *SPG7*, functional *AFG3L2* homo-oligomers

persist, in the absence of AFG3L2, there is no functional *m*-AAA protease. This might explain the differences in the severity and pattern of inheritance that result from mutations in SPG7 versus AFG3L2. Six missense mutations have been described; four in the protease domain, one in the ATPase domain, and one in a region outside any conserved domain. When the AFG3L2 mutations are expressed in *deltayta10deltayta12* yeast, the five that occur in conserved regions fail to rescue respiratory growth or proteolytic activity (212). In the patients, no defect is observed in skeletal muscle. The authors' suggest that the neuron-specific phenotype may be due to differences in homo- versus hetero-oligomeric subunit composition in the affected cell types which may result from tissue specific differences in the relative expression of each subunit (199).

8. RESPIRATORY COMPLEXES

Respiratory complexes are multisubunit assemblies which, except for Complex II, incorporate proteins encoded by both the mitochondrial and nuclear genomes. Thus the biogenesis of the OXPHOS system is a complicated and highly regulated process that involves chaperones and assembly factors that facilitate complex assembly as well as the insertion of cofactors (FAD, Fe/S, hemes, and Cu) required for electron transport (reviewed in (213)). Given this complicated process, not surprisingly, mutations associated with disease reside within both genomes and target not only subunits of the OXPHOS complexes, but also proteins required for their proper assembly. Again, yeast lacks respiratory complex I and is thus not a suitable model to study this abundant class of mitochondrial disease. However, yeast has proven invaluable in characterizing mutant proteins required for the proper function of the other OXPHOS components (Figure 1), as detailed below.

8.1. Complex II

8.1.1. Complex II subunits—Succinate dehydrogenase (SDH) is simultaneously involved in two metabolic processes: in the TCA cycle, it oxidizes succinate to fumarate; and in the electron transport chain, it transfers electrons from succinate to coenzyme Q (CoQ) (Figure 2A). In mammals, SDH is composed of 4 nuclear encoded subunits, SDHA-D, which are homologous to yeast Sdh1–4p. SDHA/Sdh1p is a flavoprotein that, with the Fe/S protein SDHB/Sdh2p, forms the catalytic core of SDH. SDHC/Sdh3p and SDHD/Sdh4p anchor the catalytic core to the matrix side of the IM and are the site of CoQ reduction (reviewed in (214, 215)).

Seven mutations in SDHA have been shown to cause Leigh syndrome (216–221). Leigh syndrome is a genetically heterogeneous disease that results from a deficiency in ATP production (222). It is a progressive neurodegenerative disorder characterized by focal, bilateral spongiform lesions of the central nervous system, and presents as intellectual retardation, nystagmus, optic atrophy, ophthalmoparesis, ataxia, dystonia, and abnormal breathing rhythm (222).

When the first SDHA mutation in Leigh syndrome patients was identified, the mutation was introduced into yeast Sdh1p. Compared to wild type, the mutant Sdh1p has a 50% decrease in SDH activity, providing evidence that the detected *SDHA* mutation was a *bona fide* pathogenic mutant, and that the symptoms were not the cause of some other, undetected mutation (216). It should be noted that this was the first defined mitochondrial disease-associated mutation of a nuclear encoded mitochondrial protein.

Mutations in SDH also cause autosomal dominant inheritable forms of cancer, such as head and neck paragangliomas, pheochromocytomas (217), and renal cell cancer (223). SDH acts as a classic tumor suppressor, where loss of function leads to tumorigenesis. The wild type allele is often deleted in patient tumors. This loss of heterozygosity completely abolishes

SDH activity because the only remaining allele is non-functional (224, 225). Over 300 unique mutations have been found that cause paraganglioma/pheochromocytomas, spanning all four SDH subunits (217).

While the mechanism of how SDHA mutations cause Leigh syndrome is straightforward, how SDH mutations lead to tumorigenesis is less clear. Two non-mutually exclusive hypotheses have emerged (Figure 2B). In the ROS hypothesis, it is proposed that mutations in SDHB-D cause SDH defects, allowing for the uncoupled flow of electrons from succinate to oxygen or water (226, 227). Essentially, electrons enter complex II by virtue of the SDH activity of SDHA but they are unable to reduce CoQ. The generated ROS then can either mutagenize nuclear proto-oncogenes and/or tumor suppressors, or instead stabilize hypoxia inducible factor-1 alpha (HIF-1 alpha). HIF-1 alpha induces the expression of genes involved in angiogenesis, proliferation, cell survival, and glycolysis; pathways that would benefit a tumor (228).

The recent identification of a pathogenic SDHA mutation causing paraganglioma while inhibiting SDH activity (no succinate oxidation and thus electrons do not enter complex II; (229)) argues against ROS generation as the only tumorigenic mechanism. In yeast harboring pathogenic mutations in Sdh2p, Sdh3p, or Sdh4p, increased ROS production is observed and the mutant yeast are hypersensitive to oxidative stress (227, 230). However, there is conflicting evidence as to whether the ROS generated in the mutants is sufficient to cause mtDNA damage (231, 232).

The second mechanism involves the accumulation of succinate. With impaired/absent SDH activity, succinate builds up in the matrix, and is transported into the cytoplasm by the dicarboxylate carrier (227, 232). Cytosolic succinate can then act as an inhibitor of alpha-ketoglutarate-dependent enzymes including prolyl hydroxylases that normally facilitate the rapid ubiquitin-dependent removal of HIF-1 alpha (233). Succinate-mediated inhibition of HIF-1 alpha prolyl hydroxylases thus stabilizes the normally transient HIF-1 alpha resulting in the activation of numerous tumor-promoting pathways (228). As both ROS and succinate can impinge at the level of HIF-1 alpha stabilization by inhibiting the HIF-1 alpha prolyl hydroxylases, both models are likely to contribute to tumorigenesis associated with *SDH* mutations.

8.1.2. Complex II assembly factors—Two SDH assembly factors have recently been identified. Sdh5p was identified in yeast as a soluble protein located in the matrix that is required for SDH activity but is not a stable component of complex II. In the absence of Sdh5p, Sdh1p is not flavinated, and therefore non-functional. In the human ortholog, hSDH5/SDHAF2 (SDH Assembly Factor 2), a G78R mutation was found in a Dutch paraganglioma lineage that co-segregated with the disease (234). As predicted based on the yeast studies, SDHA flavination is reduced by 95% in these patients. Growth on respiratory media of *delta_{sdh5}* yeast can be rescued by wild type human SDHAF2, but not when the pathogenic mutant SDHAF2 is expressed.

Two mutations have been described in a second SDH assembly factor, SDHAF 1, in patients with infantile leukoencephalopathy (235–237). The yeast ortholog was deleted, revealing an inability to grow on respiratory media. When the pathogenic mutations G57R and R55P were modeled in the yeast gene (as G63R and R61P), SDH activity is decreased to 30–40% of wild type and respiratory growth inhibited. However, COX enzymatic activity, respiration, and cytochrome spectra show no abnormalities, indicating that the shortcoming is due to SDH deficiency and not a generalized respiratory defect (237). Thus, SDHAF1 functions as an evolutionarily conserved assembly factor, although further studies are necessary to determine its precise molecular function.

8.2. Complex III

8.2.1. Complex III subunits—The cytochrome *bc₁* complex (complex III) transfers electrons from CoQ to cytochrome *c*. In mammals, Complex III consists of 11 subunits, whereas in yeast complex III only contains 10 subunits. Three catalytic subunits are responsible for electron transfer: cytochrome *b* (Cobp; the only subunit encoded in the mitochondrial genome), cytochrome *c₁* (Cyt1p), and the Rieske Fe/S protein (Rip1p) (238, 239).

There are currently 33 reported COB mutations (14) that result in a variety of symptoms, including cardiomyopathy, myopathy, exercise intolerance, Leber's hereditary optic neuropathy, Kearns-Sayre syndrome, MELAS, and maternally inherited Leigh syndrome (14, 240). In addition, non-pathogenic polymorphisms have been described (241).

Modeling patient mutations in yeast has not only helped to distinguish between pathogenic and silent mutations, but also facilitated elucidation of the mechanism of complex III dysfunction. For example, when the pathogenic mutants K319P, G33S, S152P, and G291D are modeled in yeast, there is a decrease in steady state abundance of complex III subunits, implying that the mutations introduce structural changes into Cobp that either destabilize the enzyme, or prevent its assembly (242, 243). On the other hand, the pathogenic mutants E272D, E272Q, and Y279C all decrease the binding affinity of quinol (reduced CoQ; (243, 244)), and G167E alters the interaction between cytochrome *b* and Rip1p, hindering Rip1p movement and decreasing the catalytic rate of complex III (245).

8.2.2. Complex III Assembly Factors—*BCS1* was first identified from a yeast mutant screen as being involved in the assembly of Rip1p (246). It resides in the inner membrane, and is an AAA protein family member. Required at a late stage in complex III biogenesis, Bcs1p binds to a complex III subcomplex in an ATP-dependent manner, and facilitates the incorporation of Rip1p (247).

Mutations in *BCS1L*, the human ortholog of yeast *BCS1*, result in a variety of phenotypes: complex III deficiency (248–251), which is manifested as neonatal tubulopathy, encephalopathy, and liver failure; GRACILE syndrome (252), characterized by growth retardation, aminoaciduria, cholestasis, iron overload, lacticidosis, and early death; and Björnstad syndrome (253), which presents as sensorineural hearing loss and pili torti.

In most studies of pathogenic *BCS1L* mutations, the human gene is expressed in a *delta bcs1* strain, and the ability to grow on respiratory media assessed. Wild type human *BCS1L* provides a partial rescue of the *delta bcs1* yeast growth defect (248), suggesting that despite the high similarity between the yeast and human proteins, subtle differences exist. Still, the growth assay provides a means to determine the severity of a pathogenic mutation. For instance, the R155P mutation causing complex III deficiency results in a complete loss of respiratory growth, while the S277N mutation retains some growth, albeit severely reduced when compared to wild type *BCS1L*. However, corresponding differences in the respiratory complex enzymatic activity in patients harboring these particular mutations is not observed (248). When a *BCS1L* mutant associated with GRACILE syndrome is placed in a *delta bcs1* yeast strain, the respiratory growth defect is not rescued indicating a loss of function. However, curiously, biopsies of the patient's tissue revealed no defect in complex III function (252).

A *BCS1L* mutation associated with complex III deficiency, R45C, results in severe complex III deficiency in patient tissue (249), but surprisingly, when the mutation is modeled at the equivalent residue in the yeast Bcs1p, no growth abnormality or complex III defect is observed (254). The observed difference between the human patient and the yeast model

likely reflects subtle differences in mitochondrial targeting in yeast and mammals. The two other BCS1L mutations from the same study, K192 and F401I, displayed the expected phenotype of no respiratory growth and stable complex III subcomplexes at the expense of fully assembled complex III (254).

8.3. Complex IV

8.3.1. Complex IV subunits—Cytochrome *c* oxidase (COX or complex IV) transfers electrons from cytochrome *c* to O₂. It consists of 3 mitochondrially encoded subunits, Cox1p, Cox2p, and Cox3p. Cox1p and Cox2p contain the heme groups (*a* and *a*₃) and copper centers (Cu_A and Cu_B) required for electron transfer. Cox3p may provide a structural role in stabilizing the catalytic core, or play a role in proton pumping (reviewed in (255)). The additional subunits (10 in mammals, 8 in yeast) stabilize the catalytic core, but are nonetheless essential for COX function, since the disruption of most subunits abolishes COX assembly (256).

COX deficiency is one of the most common respiratory chain defects in humans. Mutations in the mitochondrially encoded subunits present heterogeneous clinical phenotypes, including Leigh syndrome, MELAS, encephalomyopathy, myopathy, motor neuron-like degeneration, myoglobinuria, and Sideroblastic anemia (256, 257).

When the I280T COX1 mutant is modeled in yeast, respiratory growth is decreased, and COX activity is reduced to 50% of wild type. Although no decrease in overall COX content (as determined by cytochrome *a* spectra) is detected, the authors noted a subpopulation of the enzyme that is unable to bind cyanide or carbon monoxide (258), two inhibitors of COX. Potentially, the mutation affects assembly or decreases the stability of the holoenzyme, creating a minor population of misassembled or disassembled complexes. Alternatively, the mutation may increase the probability that Cox1p will misfold, resulting in a non-reactive binuclear center (the site of O₂ reduction in COX). Another COX1 mutant, M273T, also shows decreased respiratory growth and COX activity, while retaining wild type levels of cytochrome *a*. Unlike I280T, the M273T mutant displays an increased reaction rate of carbon monoxide with COX (258). Since these mutations occur near the conserved K channel, which provides access of H⁺ from the matrix to the binuclear center (259), the rate of electron transfer from heme *a* to the binuclear center may be reduced, decreasing O₂ consumption (258).

Interestingly, the G317S COX1 mutant, which was detected in a patient presenting with COX deficiency and lactic acidosis, shows no COX defect when modeled in yeast, despite occurring at a conserved residue. Respiratory growth, COX activity, and cytochrome *a* content in the mutant is indistinguishable from wild type strains (258). Additional studies using patient-derived cells determined that the COX defect was of nuclear origin (260). Additionally, mutations L196I and A223S were identified in patients, but the yeast models display no COX defects (261). These mutations are now considered silent polymorphisms (14). These examples highlight the power of yeast models to distinguish between pathogenic mutations and neutral polymorphisms.

When the pathogenic deltaF102-F106 microdeletion is modeled in yeast Cox3p, respiratory growth is absent, and no COX activity is detected (258), consistent with the results seen in patient-derived tissue culture (262). A respiratory growth defect is also seen in a mutation resulting in a premature stop codon at residue 249 of Cox3p (261). This is in contrast to identified patient mutations G78S and A200T which display no defect when modeled in yeast Cox3p (261), and have also been reclassified as silent polymorphisms (14).

To date, only one mutation has been described in a nuclear-encoded COX subunit, COX6B1. Wild type COX6 is able to complement *deltacox12* yeast (yeast Cox12p is the ortholog of human COX6). *Deltacox12* yeast expressing mutant COX6 grow at a slower rate than wild type on respiratory media. Given that *deltacox12* yeast are unable to grow on respiratory media, these results indicate that the mutant protein still retains some function. Consistent with this, while oxygen consumption is 25% lower in the mutant than in wild type (263), there is no oxygen consumption in the *deltacox12* strain. Interestingly, Cox12p is one of the few COX subunits that are not absolutely required for COX activity once the enzyme is fully assembled (264).

8.3.2. Complex IV assembly factors—Over 20 additional proteins are required for the proper assembly of COX in yeast (reviewed in (255)). The human orthologs of many have been identified (265–267). In yeast, COX assembly begins with the translation of *COX1* which is enhanced by the Cox1p translational activator, Mss51p (268). In addition to functioning as a Cox1p translational enhancer, Mss51p additionally functions as a chaperone, which together with Cox14p and Coa3p (Cytochrome Oxidase Assembly), binds and stabilizes unassembled Cox1p (256, 269, 270). Worth mentioning, Mss51p in complex with unfolded Cox1p is unable to further stimulate Cox1p translation. Thus, in the absence of productive COX assembly, Mss51p is titrated out resulting in a drop in Cox1p production. Coa1p association then releases Mss51p and Cox14p and promotes further Cox1p maturation (271, 272). The next step is believed to involve Cox11p and Shy1p which are required for the addition of the Cu_B cofactor to Cox1p, and Coa2p, Cox10p, and Cox15p, the latter two generating the heme *a* that is uniquely utilized by COX (273–276). Cofactor loaded Cox1p is further stabilized by two nuclear encoded subunits, Cox6p and Cox5p (277). The addition of Cu_A to Cox2p involves the Cu chaperone Cox17p, which traffics between the cytosol and IMS, and the copper binding protein Sco1p (and SCO2 in humans) (13, 278, 279). Steps downstream of this are at present ill-defined as are the exact mechanisms for the attachment of the numerous COX cofactors.

The yeast gene *SHY1*, and its human ortholog *SURF1*, is required for full COX activity (280), although its precise function remains incompletely defined. Mutations in *SURF1* cause Leigh syndrome (281–283) via COX deficiency. Surprisingly, patients' harboring *SURF1* mutations still retain 10–30% normal COX activity. This indicates that either *SURF1* is not absolutely required for COX assembly or that partially redundant activities exist.

When Leigh syndrome *SURF1* missense mutations are modeled in Shy1p, mutants F249T and Y344D exhibit wild type levels of COX activity (284), although a cold sensitive phenotype on respiratory media is observed for the Y344D Shy1p mutant (285). The Y334D Shy1p mutant results in a destabilization of newly synthesized Cox1p, and an uncoupling of Cox1p translation from assembly (285). In contrast, when G137 is mutated to either Glu or Arg, both of which are pathogenic mutations, Shy1p is imported efficiently into mitochondria, but is degraded rapidly, resulting in much lower steady state levels of the mutant Shy1p (285). The G137E mutant was also used to screen for suppressors, which identified the previously known assembly factors Coa2p and Cox10p, as well as the novel assembly factor Coa4p (284).

Yeast *SCO1* and *SCO2* were first identified as high copy suppressors of the COX assembly factor Cox17p (13), a soluble protein that transfers Cu to the IM protein Sco1p (279, 286). Sco1p is able to bind Cu via the CXXXC motif (287, 288) and physically associate with Cox2p, although this association is not dependent on either Cu or conserved Cu binding residues (289). These observations have led to two models for Sco1p mediated Cu delivery to COX. Sco1p could directly transfer Cu from Cox17p to Cox2p (13). Or instead, Sco1p

could reduce cysteine residues in Cox2p which is necessary for Cu binding (290). Despite homology with Sco1p, *deltasco2* yeast exhibit no COX deficiency and Sco2p overexpression cannot rescue a yeast *sco1* null mutant (13).

Humans also contain *SCO1* and *SCO2*; however sequence analysis shows that both human *SCO* genes display similar divergence from both yeast *SCO* genes, suggesting that gene duplication occurred independently in both yeast and humans, producing two sets of paralogous genes (291). Unlike yeast, both human *SCO* proteins are required for viability, and have non-overlapping functions in COX assembly (292).

The non-overlapping functions of human *SCO* genes is further supported by their clinical pathologies. Mutations in *SCO1* cause hepatopathy and ketoacidotic coma (293), while mutations in *SCO2* are associated with infantile cardiomyopathy (291, 294).

Human *SCO1* is not able to rescue *deltasco1* yeast. However, chimeric yeast/human *SCO1*, consisting of an N-terminal yeast Sco1p and C-terminal human *SCO1*, is able to rescue *deltasco1* yeast (295). When the pathogenic mutation P174L is modeled in the chimeric protein (with the mutation occurring in the C-terminal human half of the protein), the mutant *SCO1* is non-functional (296). The mutation occurs immediately adjacent to the CXXXC motif required for Cu binding (288), implying that the mutation affects the Cu binding ability of the mutant *SCO1*, although this still needs to be directly tested.

Yeast Sco1p has also been used to model human *SCO2* mutations. The mutation E155K in yeast Sco1p, matching the pathogenic E140K mutation in human *SCO2*, is able to rescue COX activity in yeast, although the steady state expression of the mutant Sco1p is slightly reduced (297). This is surprising since E140 is located only 3 amino acids away from the CXXXC motif and was predicted to negatively impact Cu binding of the mutant protein, similar to the pathogenic P174L *SCO1* mutant. As such, this may illustrate subtle differences between the structure and/or function of yeast and human *SCO* proteins.

The S240F mutation, modeling the pathogenic human *SCO2* mutation S225F, results in a dramatic COX defect (297). As with a *deltasco1* strain, Cox2p expression in the mutant is abolished, likely indicating that the mutant is unable to deliver Cu to Cox2p, which is then degraded. Interestingly, cytochrome *aa₃* analysis suggests that COX may partially assemble, despite the complete absence of Cox2p, possibly demonstrating that the Sco1p polypeptide plays a role in stabilizing COX subassemblies independent of its role in metallating Cox2p (297).

Finally, it is worth mentioning that basic work on the biogenesis of COX in yeast has guided efforts to identify the basis of human COX deficiencies. One approach that has been successfully employed is to attempt to rescue COX-deficient patient-derived cells by overexpressing various human orthologs of COX assembly factors identified and characterized first in yeast. Such efforts have identified mutations in the heme A biosynthetic genes, *COX10* and *COX15*, in patients suffering from the entire range of phenotypes associated with COX deficiency or an early onset fatal cardiomyopathy, respectively (298, 299). Thus, in addition to defining the function of wild type genes and determining whether mutations are pathogenic or silent, work in yeast has guided efforts to identify pathogenic lesions in patients without prior molecular diagnoses.

8.4. Complex V

8.4.1. Complex V subunits—The mitochondrial ATP synthase utilizes the proton gradient generated by the other respiratory complexes to condense ATP from ADP and P_i (Figure 1). The ATP synthase consists of two functional units. F₁ faces the matrix and is

hydrophilic. It consists of 5 subunits (3 alpha, 3 beta, gamma, delta, and epsilon), and is the section that generates ATP (or hydrolyzes it when not attached to the F_0). F_0 is hydrophobic and embedded in the inner membrane. It consists of 8 different subunits and mediates proton translocation through the oligomeric ring of c subunits (Atp9p in yeast). Only three subunits are encoded by the mitochondrial genome, Atp6p, Atp8p, and Atp9p, all of which are components of the F_0 (300).

Mutations in *ATP6* present with a range of phenotypes, from severe infantile maternally inherited Leigh syndrome (MILS), to adult onset neuropathy, ataxia, and retinitis pigmentosa (NARP) (301). Pathogenic mutations have been modeled in yeast to better understand the mechanism of ATP synthase dysfunction. The L183R Atp6p mutant decreases ATP synthesis by 90%, and decreases COX content by 95%. Despite the functional defect, ATP synthase assembles properly, indicating that the defect is catalytic in nature (302). When the same residue was mutated to Pro, ATP synthesis is only reduced by 40–50%, and COX abundance is decreased. BN-PAGE analysis showed an increased abundance of ATP synthase subcomplexes, indicating that the stability of the ATP synthase is reduced when this mutation is present (303).

Two pathogenic mutations at Leu 247 of Atp6p were also modeled. The L247R mutation causes complete ATP synthase disassembly, with a 95% decrease in ATP synthesis. The defect represents a complete loss of function, as it mimics the phenotype of *deltaatp6* yeast (304). The L247P phenotype, on the other hand, is much less severe. ATP production is only decreased by 50%, and the complex displays increased instability (305). As with other yeast models, the authors note that the severity of the defect when each mutation is modeled in yeast correlates well to the severity of symptoms in patients.

8.4.2. Complex V assembly factors—Of the ATP synthase assembly factors identified in yeast ((306) and reviewed in (307)), only Atp11p and Atp12p have functional homologs identified in humans (308). Studies in yeast have shown that Atp11p and Atp12p bind selectively to newly imported beta and alpha subunits of F_1 , respectively (309), acting as chaperones to facilitate the assembly of the alpha/beta hexamer of F_1 . In the absence of either Atp11p or Atp12p, F_1 alpha and F_1 beta form large insoluble aggregates in the mitochondrial matrix (306).

A missense mutation, W94R, in human ATP12 has been reported in a patient presenting with lactic acidosis, dysmorphic features, and methyl glutaconic aciduria. The patient showed a severe defect in ATP synthase activity, as well as less severe defects in other respiratory complexes (310). Although many structure/function studies have been performed with Atp12p in yeast (reviewed in (311)), the molecular mechanism of the pathogenic mutant remains unknown, since it occurs outside of the functional domain, and point mutations at the homologous residue have not been reported.

9. IRON HOMEOSTASIS

Friedreich ataxia is a progressive autosomal recessive neurodegenerative disorder, causing ataxia in all four limbs, dysarthria, sensory loss, and muscle weakness. Most patients also present with skeletal deformities and cardiomyopathy (312). The disease-causing gene was identified as *FRAXIN* (*FXN*), and it was noted that most pathogenic mutations were the result of GAA repeat expansions in the first intron (313). While most patients are homozygous for the expansion, others harbor the expansion in one allele and missense mutations in the other (312). Both forms of the *FXN* are thought to be loss of function mutations.

At the time of its identification, nothing was known about the function of FXN, other than it contained a putative N-terminal mitochondrial localization sequence. Homologs were identified in yeast and in *C.elegans* (313). Interestingly, the yeast homolog, *YFH1*, was identified as a high copy suppressor of the *bm-8* mutant, which is unable to grow on iron-limited media (314). Yfh1p was shown to be localized to mitochondria (314, 315), and disruption of the gene causes a *petite* phenotype associated with mtDNA instability (314–316). Pathogenic point mutations from patients were modeled in Yfh1p, and display a severe defect in respiratory capacity and mtDNA stability (315).

That Yfh1p was identified as a suppressor of *bm-8* implicated it in iron homeostasis. Indeed, studies in yeast have shown that in the absence of Yfh1p function, iron accumulates in mitochondria (314) at the expense of cytosolic iron (317). Importantly, iron accumulation is also seen in patients (318). Further demonstrating functional conservation between Yfh1p and human FXN, iron accumulation is rescued in *deltayfh1* yeast expressing the human *FXN* gene (319). When the pathogenic mutation G130V, associated with a mild clinical presentation, is generated in FXN and expressed in *deltayfh1* yeast, mutant FXN is properly imported into mitochondria but destabilized compared to wild type FXN. Surprisingly, despite the decreased abundance, this mutation is still sufficient to rescue the *deltayfh1* phenotype. In contrast, when a mutant FXN with a more severe clinical phenotype, W173G, is expressed in *deltayfh1* yeast, both FXN processing and stability are decreased, and the mutation is unable to rescue *deltayfh1*. These studies not only provide separate mechanisms for FXN dysfunction, but also show a good correlation between clinical severity and the extent of the phenotype in yeast.

Studies in yeast have also helped to elucidate the molecular function of Yfh1p/FXN. At low levels of mitochondrial iron, Yfh1p exists as a monomer. However, at increased iron concentrations Yfh1p forms higher-order oligomers capable of sequestering up to 75 iron atoms per Yfh1p monomer (320–322) and, in-so-doing, preventing iron toxicity. This may provide a pathogenic mechanism for Friedreich ataxia. Without sequestration of iron, ROS can be generated and damage mtDNA, which is consistent with the *petite* phenotype of the *deltayfh1* strain.

However, Yfh1p was also shown to serve as an iron chaperone, keeping iron in a bioavailable form (322). Consistent with this, Yfh1p has been shown to physically interact with a subunit of SDH (323), which contains Fe/S centers; and Isu1p (324), the scaffold protein in the Fe/S cluster-assembly complex. The importance of Yfh1p/FXN in Fe/S cluster biosynthesis is seen in the lack of SDH and aconitase activity in both *deltayfh1* yeast strains (325) and Friedreich ataxia patients (326). Notably, Fe/S containing enzymes such as aconitase (an enzyme of the TCA cycle) and Sdh2p are highly susceptible to ROS mediated attack and inactivation, and FXN has been suggested to directly function as a chaperone that is capable of aconitase reactivation (327). Thus, FXN's role as an iron chaperone provides another possible mechanism for the respiratory defect seen in *deltayfh1* yeast (315) and patients suffering from Friedreich ataxia (326).

10. CARDIOLIPIN BIOSYNTHESIS

The lipid cardiolipin (CL) is enriched in mitochondrial membranes, especially the inner membrane, its site of synthesis (328). CL is an unusual lipid consisting of two phosphatidyl moieties bridged by glycerol. As such, CL contains four fatty acyl chains (Figure 3A) (329). When cardiolipin synthase forms CL from phosphatidylglycerol and cytidine diphosphate-diacylglycerol, the result is immature CL characterized by saturated acyl chains of variable length (Figure 3B) (330). Immature CL then undergoes a remodeling process in which the acyl chains are replaced with more unsaturated fatty acyl chains, forming mature CL, which

displays a high degree of molecular symmetry (329). The remodeling process is initiated by a phospholipase (Cld1p in yeast), which removes an acyl chain, forming monolysocardiolipin (MLCL) (331). The MLCL transacylase, TFAZZIN (Taz1p in yeast), then takes an acyl chain from another phospholipid (preferentially phosphatidylcholine or phosphatidylethanolamine) and adds it to MLCL thus regenerating CL (332). Through a series of such reactions, immature CL is converted to mature CL. Worth noting, the final form of CL in different tissues/organisms is not the same. However, within a given tissue, the molecular form of CL with respect to its acyl chain composition is highly homogenous ((333), for a review of CL metabolism, see (334)).

CL is associated with proteins involved in a diverse array of functions, including protein import (335–338); mitochondrial fusion (176); metabolite translocation (339–351); and OXPHOS (352–359). In fact, CL is bound to all the major OXPHOS components: respiratory complexes I, III, IV, and V, cytochrome *c*, ANT, and the phosphate carrier. Despite this, yeast lacking cardiolipin synthase (*deltacrd1*) and thus CL, retain the ability to respire, although respiration is significantly diminished at elevated temperature (360, 361). Thus, while CL is not absolutely required for OXPHOS, it increases both OXPHOS efficiency and the dynamic range of conditions at which OXPHOS can function. Consistent with this, CL is required for the formation and/or stability of respiratory supercomplexes (362–364), large, multi-complex assemblies that in yeast consist of two complex IIIs and one or two complex IVs (365–367), and Aac2p-containing complexes, including an interaction between Aac2p and the respiratory supercomplex (368). Collectively, these higher order assemblies are thought to increase OXPHOS efficiency by substrate channeling.

Mutations in *TFAZZIN* result in Barth syndrome (BTHS), an X-linked disease that presents as cardiac and skeletal myopathy, delayed growth until puberty, and cyclic neutropenia (330, 369). In addition, general respiratory chain deficiencies are observed (369–372), perhaps reflecting destabilized respiratory supercomplexes (373). In BTHS patients, CL levels are decreased and the acyl chain composition is notably abnormal (374). In addition, MLCL, the intermediate in the CL remodeling pathway, accumulates in the heart, skeletal muscle, lymphocytes, and lymphoblasts of BTHS patients (375).

Deltataz1 yeast accumulate MLCL with a concurrent decrease in CL, which displays an immature acyl chain composition (376–380). In addition, yeast lacking Taz1p function display a growth defect on respiratory media at 37°C (378, 380). Consistent with BTHS patients, respiratory supercomplex assembly/stability has been reported in some (381), but not all (382) *deltataz1* yeast strains. Although 12 splice variants of human TAZ1 have been identified (383), only the splice variant lacking exon 5 is able to rescue *deltataz1* yeast (380, 384). Yeast Taz1p has been shown to assemble in distinct high molecular weight complexes with Aac2p and ATP synthase, as well as smaller complexes consisting of presently unidentified Taz1p binding partners (382). These former associations provide a direct link between Taz1p and the OXPHOS machinery that might explain some of the respiratory abnormalities observed in BTHS patients in addition to the documented defects in the levels and/or form of CL.

Of the 21 BTHS missense mutations that occur in regions of Taz1p conserved between humans and yeast, 18 are unable to rescue *deltataz1* yeast based on the significant accumulation of MLCL relative to *deltataz1* expressing wild type Taz1p (377). Of the four modeled BTHS mutations occurring in the interfacial membrane anchor, three mutations (V223D, V224R, and I226P) result in mislocalization of the mutant Taz1p to the mitochondrial matrix, while the G230R Taz1p mutant forms aberrant higher-order complexes (376).

Four other yeast BTHS mutants, A88R/E, S140R, and L148H, display reduced steady state expression when modeled in yeast Taz1p. These mutants are degraded by the *i*-AAA protease, and in the absence of the *i*-AAA protease, their steady state expression is returned to normal levels. Surprisingly, the activity of two mutants, A88E and L148H, is restored in the absence of the *i*-AAA protease. However, complexes containing these mutants are unstable, and rapidly disassemble (377). Potentially, a therapeutic strategy could be developed for this subset of BTHS patients that involves stabilizing the mutant Taz1p complexes.

Although the yeast model of BTHS mutations has provided possible pathogenic mechanisms for Taz1p loss of function, it is unclear if these mechanisms are conserved in patients. Unfortunately, robust biochemical characterization in higher systems is hampered by the lack of antibodies against mammalian TAZ1 isoforms. As such, yeast is currently the best model to understand the molecular mechanisms causing BTHS.

11. PERSPECTIVES

The yeast model is not without its limitations. Diseases affecting complex I represent a significant portion of respiratory chain defects and cannot be modeled in *S.cerevisiae*. That yeast quickly become homoplasmic also prevents a critical dissection of the threshold effect. Finally, models in multicellular organisms are required to understand the tissue specific phenotypes exhibited by many mitochondrial diseases.

Despite this, the conservation of mitochondrial function between yeast and humans make yeast an invaluable model for elucidating basic mitochondrial processes, as well as providing a better understanding of mitochondrial disease (Figure 4). The ability to efficiently generate mutations, even within mtDNA, has provided a greater understanding of the molecular mechanisms underlying disease (Table 1), which will ultimately enhance the ability to design specific therapeutic treatments. The yeast model has also proven to unambiguously distinguish between pathogenic mutations and silent polymorphisms which is critical for appropriate genetic counseling. Finally, basic research using yeast and focused on questions of fundamental importance concerning mitochondrial biogenesis and physiology provide logical candidates for assorted mitochondrial diseases which has already, and will continue, to streamline the important task of identifying the pathogenic lesions that cause mitochondrial disease. As such, the contribution of the yeast model to the field of mitochondrial medicine is immeasurable.

Acknowledgments

This work was supported a Predoctoral Fellowship from the American Heart Association 10PRE3280013 (MGB) and National Institutes of Health Grant R00HL089185 (SMC).

Glossary

AAA	ATPase associated with various cellular activities
AAC	ADP/ATP carrier
ANT	adenine nucleotide translocase
BTHS	Barth syndrome
CCCP	carbonyl cyanide m-chlorophenyl hydrazone
CL	cardiolipin

CMT2A	Charcot-Marie-Tooth disease type 2A
CoQ	coenzyme Q
COX	cytochrome c oxidase
FAD	flavin adenine dinucleotide
GED	GTPase effector domain
GRACILE	growth retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis, and early death
HIF-1 alpha	hypoxia inducible factor-1 alpha
HSP	hereditary spastic paraplegia
IM	mitochondrial inner membrane
IMS	inner membrane space
MEF	mouse embryonic fibroblast
MELAS	mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke
MERFF	myoclonic epilepsy with ragged red fibers
l-Mgm1p	long isoform of Mgm1p
s-Mgm1p	short isoform of Mgm1p
MILS	maternally inherited Leigh syndrome
MLCL	monolysocardiolipin
mtDNA	mitochondrial DNA
NARP	neuropathy, ataxia, and retinitis pigmentosa
OM	mitochondrial outer membrane
OXPHOS	oxidative phosphorylation
PAM	presequence translocase-associated motor
PEO	progressive external ophthalmoplegia
ROS	reactive oxygen species
SAM	sorting and assembly machinery
SDH	succinate dehydrogenase
SNP	single nucleotide polymorphism
TCA	tricarboxylic acid
TIM	translocase of the inner membrane
TOM	translocase of the outer membrane

REFERENCES

1. Calvo SE, Mootha VK. The mitochondrial proteome and human disease. *Annu Rev Genomics Hum Genet.* 2010; 11:25–44. [PubMed: 20690818]
2. Reinders J, Zahedi RP, Pfanner N, Meisinger C, Sickmann A. Toward the complete yeast mitochondrial proteome: multidimensional separation techniques for mitochondrial proteomics. *J Proteome Res.* 2006; 5(7):1543–1554. [PubMed: 16823961]

3. Sickmann A, Reinders J, Wagner Y, Joppich C, Zahedi R, Meyer HE, Schonfisch B, Perschil I, Chacinska A, Guiard B, Rehling P, Pfanner N, Meisinger C. The proteome of *Saccharomyces cerevisiae* mitochondria. *Proc Natl Acad Sci U S A*. 2003; 100(23):13207–13212. [PubMed: 14576278]
4. Terpstra P, Butow RA. The role of var1 in the assembly of yeast mitochondrial ribosomes. *J Biol Chem*. 1979; 254(24):12662–12669. [PubMed: 387794]
5. Schaefer AM, Taylor RW, Turnbull DM, Chinnery PF. The epidemiology of mitochondrial disorders--past, present and future. *Biochim Biophys Acta*. 2004; 1659(2–3):115–120. [PubMed: 15576042]
6. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, Wong LJ, Cohen BH, Naviaux RK. The in-depth evaluation of suspected mitochondrial disease. *Mol Genet Metab*. 2008; 94(1):16–37. [PubMed: 18243024]
7. Thorburn DR. Mitochondrial disorders: prevalence, myths and advances. *J Inherit Metab Dis*. 2004; 27(3):349–362. [PubMed: 15190193]
8. Thorburn DR, Sugiana C, Salemi R, Kirby DM, Worgan L, Ohtake A, Ryan MT. Biochemical and molecular diagnosis of mitochondrial respiratory chain disorders. *Biochim Biophys Acta*. 2004; 1659(2–3):121–128. [PubMed: 15576043]
9. Wallace DC. Mitochondrial diseases in man and mouse. *Science*. 1999; 283(5407):1482–1488. [PubMed: 10066162]
10. Rinaldi T, Lande R, Bolotin-Fukuhara M, Frontali L. Additional copies of the mitochondrial Ef-Tu and aspartyl-tRNA synthetase genes can compensate for a mutation affecting the maturation of the mitochondrial tRNA^{Asp}. *Curr Genet*. 1997; 31(6):494–496. [PubMed: 9211792]
11. Hasson SA, Damoiseaux R, Glavin JD, Dabir DV, Walker SS, Koehler CM. Substrate specificity of the TIM22 mitochondrial import pathway revealed with small molecule inhibitor of protein translocation. *Proc Natl Acad Sci U S A*. 2010; 107(21):9578–9583. [PubMed: 20457929]
12. Schuldiner M, Collins SR, Thompson NJ, Denic V, Bhamidipati A, Punna T, Ihmels J, Andrews B, Boone C, Greenblatt JF, Weissman JS, Krogan NJ. Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile. *Cell*. 2005; 123(3):507–519. [PubMed: 16269340]
13. Glerum DM, Shtanko A, Tzagoloff A. SCO1 and SCO2 act as high copy suppressors of a mitochondrial copper recruitment defect in *Saccharomyces cerevisiae*. *J Biol Chem*. 1996; 271(34):20531–20535. [PubMed: 8702795]
14. MITOMAP: A Human Mitochondrial Genome Database. 2011. In: <http://www.mitomap.org>
15. Tuppen HA, Blakely EL, Turnbull DM, Taylor RW. Mitochondrial DNA mutations and human disease. *Biochim Biophys Acta*. 2010; 1797(2):113–128. [PubMed: 19761752]
16. Ding MG, Butler CA, Saracco SA, Fox TD, Godard F, di Rago JP, Trumpower BL. Chapter 27 An improved method for introducing point mutations into the mitochondrial cytochrome B gene to facilitate studying the role of cytochrome B in the formation of reactive oxygen species. *Methods Enzymol*. 2009; 456:491–506. [PubMed: 19348906]
17. Bonnefoy N, Fox TD. Directed alteration of *Saccharomyces cerevisiae* mitochondrial DNA by biolistic transformation and homologous recombination. *Methods Mol Biol*. 2007; 372:153–166. [PubMed: 18314724]
18. Fox TD, Sanford JC, McMullin TW. Plasmids can stably transform yeast mitochondria lacking endogenous mtDNA. *Proc Natl Acad Sci U S A*. 1988; 85(19):7288–7292. [PubMed: 2459701]
19. Tyynismaa H, Suomalainen A. Mouse models of mitochondrial DNA defects and their relevance for human disease. *EMBO Rep*. 2009; 10(2):137–143. [PubMed: 19148224]
20. Xu H, DeLuca SZ, O'Farrell PH. Manipulating the metazoan mitochondrial genome with targeted restriction enzymes. *Science*. 2008; 321(5888):575–577. [PubMed: 18653897]
21. Wallace DC, Fan W. The pathophysiology of mitochondrial disease as modeled in the mouse. *Genes Dev*. 2009; 23(15):1714–1736. [PubMed: 19651984]
22. Mahato B, Jash S, Adhya S. RNA-mediated restoration of mitochondrial function in cells harboring a Kearns Sayre Syndrome mutation. *Mitochondrion*. 2011
23. DiMauro S, Moraes CT. Mitochondrial encephalomyopathies. *Arch Neurol*. 1993; 50(11):1197–1208. [PubMed: 8215979]

24. Wong LJ. Diagnostic challenges of mitochondrial DNA disorders. *Mitochondrion*. 2007; 7(1–2): 45–52. [PubMed: 17276740]
25. Birky CW Jr. The inheritance of genes in mitochondria and chloroplasts: laws, mechanisms, and models. *Annu Rev Genet*. 2001; 35:125–148. [PubMed: 11700280]
26. Shibata T, Ling F. DNA recombination protein-dependent mechanism of homoplasmy and its proposed functions. *Mitochondrion*. 2007; 7(1–2):17–23. [PubMed: 17280877]
27. Young MJ, Court DA. Effects of the S288c genetic background and common auxotrophic markers on mitochondrial DNA function in *Saccharomyces cerevisiae*. *Yeast*. 2008; 25(12):903–912. [PubMed: 19160453]
28. Baruffini E, Lodi T, Dallabona C, Foury F. A single nucleotide polymorphism in the DNA polymerase gamma gene of *Saccharomyces cerevisiae* laboratory strains is responsible for increased mitochondrial DNA mutability. *Genetics*. 2007; 177(2):1227–1231. [PubMed: 17720904]
29. Gaisne M, Becam AM, Verdiere J, Herbert CJ. A 'natural' mutation in *Saccharomyces cerevisiae* strains derived from S288c affects the complex regulatory gene HAP1 (CYPI). *Curr Genet*. 1999; 36(4):195–200. [PubMed: 10541856]
30. Zitomer RS, Lowry CV. Regulation of gene expression by oxygen in *Saccharomyces cerevisiae*. *Microbiol Rev*. 1992; 56(1):1–11. [PubMed: 1579104]
31. Dimitrov LN, Brem RB, Kruglyak L, Gottschling DE. Polymorphisms in multiple genes contribute to the spontaneous mitochondrial genome instability of *Saccharomyces cerevisiae* S288C strains. *Genetics*. 2009; 183(1):365–383. [PubMed: 19581448]
32. Giaever G, Chu AM, Ni L, Connelly C, Riles L, Veronneau S, Dow S, Lucau-Danila A, Anderson K, Andre B, Arkin AP, Astromoff A, El-Bakkoury M, Bangham R, Benito R, Brachat S, Campanaro S, Curtiss M, Davis K, Deutschbauer A, Entian KD, Flaherty P, Foury F, Garfinkel DJ, Gerstein M, Gotte D, Guldener U, Hegemann JH, Hempel S, Herman Z, Jaramillo DF, Kelly DE, Kelly SL, Kotter P, LaBonte D, Lamb DC, Lan N, Liang H, Liao H, Liu L, Luo C, Lussier M, Mao R, Menard P, Ooi SL, Revuelta JL, Roberts CJ, Rose M, Ross-Macdonald P, Scherens B, Schimmack G, Shafer B, Shoemaker DD, Sookhai-Mahadeo S, Storms RK, Strathern JN, Valle G, Voet M, Volckaert G, Wang CY, Ward TR, Wilhelmy J, Winzeler EA, Yang Y, Yen G, Youngman E, Yu K, Bussey H, Boeke JD, Snyder M, Philippsen P, Davis RW, Johnston M. Functional profiling of the *Saccharomyces cerevisiae* genome. *Nature*. 2002; 418(6896):387–391. [PubMed: 12140549]
33. Scaglia F, Wong LJ. Human mitochondrial transfer RNAs: role of pathogenic mutation in disease. *Muscle Nerve*. 2008; 37(2):150–171. [PubMed: 17999409]
34. De Luca C, Zhou Y, Montanari A, Morea V, Oliva R, Besagni C, Bolotin-Fukuhara M, Frontali L, Francisci S. Can yeast be used to study mitochondrial diseases? Biostatic tRNA mutants for the analysis of mechanisms and suppressors. *Mitochondrion*. 2009; 9(6):408–417. [PubMed: 19631764]
35. Feuermann M, Francisci S, Rinaldi T, De Luca C, Rohou H, Frontali L, Bolotin-Fukuhara M. The yeast counterparts of human 'MELAS' mutations cause mitochondrial dysfunction that can be rescued by overexpression of the mitochondrial translation factor EF-Tu. *EMBO Rep*. 2003; 4(1): 53–58. [PubMed: 12524521]
36. Montanari A, Besagni C, De Luca C, Morea V, Oliva R, Tramontano A, Bolotin-Fukuhara M, Frontali L, Francisci S. Yeast as a model of human mitochondrial tRNA base substitutions: investigation of the molecular basis of respiratory defects. *RNA*. 2008; 14(2):275–283. [PubMed: 18065717]
37. Rohou H, Francisci S, Rinaldi T, Frontali L, Bolotin-Fukuhara M. Reintroduction of a characterized Mit tRNA glycine mutation into yeast mitochondria provides a new tool for the study of human neurodegenerative diseases. *Yeast*. 2001; 18(3):219–227. [PubMed: 11180455]
38. Kolesnikova OA, Entelis NS, Jacquin-Becker C, Goltzene F, Chrzanowska-Lightowlers ZM, Lightowlers RN, Martin RP, Tarassov I. Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a mitochondrial DNA mutation associated with the MERRF syndrome in cultured human cells. *Hum Mol Genet*. 2004; 13(20):2519–2534. [PubMed: 15317755]

39. Sohm B, Frugier M, Brule H, Olszak K, Przykorska A, Florentz C. Towards understanding human mitochondrial leucine aminoacylation identity. *J Mol Biol.* 2003; 328(5):995–1010. [PubMed: 12729737]
40. De Luca C, Besagni C, Frontali L, Bolotin-Fukuhara M, Francisci S. Mutations in yeast mt tRNAs: specific and general suppression by nuclear encoded tRNA interactors. *Gene.* 2006; 377:169–176. [PubMed: 16777356]
41. Park H, Davidson E, King MP. Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene. *RNA.* 2008; 14(11):2407–2416. [PubMed: 18796578]
42. Sasarman F, Antonicka H, Shoubridge EA. The A3243G tRNA(Leu(UUR)) MELAS mutation causes amino acid misincorporation and a combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2. *Hum Mol Genet.* 2008; 17(23):3697–3707. [PubMed: 18753147]
43. McFarland R, Elson JL, Taylor RW, Howell N, Turnbull DM. Assigning pathogenicity to mitochondrial tRNA mutations: when "definitely maybe" is not good enough. *Trends Genet.* 2004; 20(12):591–596. [PubMed: 15522452]
44. DiMauro S, Andreu AL. Mutations in mitochondrial DNA as a cause of exercise intolerance. *Ann Med.* 2001; 33(7):472–476. [PubMed: 11680795]
45. Lee YS, Kennedy WD, Yin YW. Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations. *Cell.* 2009; 139(2):312–324. [PubMed: 19837034]
46. Ropp PA, Copeland WC. Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma. *Genomics.* 1996; 36(3):449–458. [PubMed: 8884268]
47. Foury F. Cloning and sequencing of the nuclear gene MIP1 encoding the catalytic subunit of the yeast mitochondrial DNA polymerase. *J Biol Chem.* 1989; 264(34):20552–20560. [PubMed: 2684980]
48. Stumpf JD, Copeland WC. Mitochondrial DNA replication and disease: insights from DNA polymerase gamma mutations. *Cell Mol Life Sci.* 2011; 68(2):219–233. [PubMed: 20927567]
49. Baruffini E, Ferrero I, Foury F. *In vivo* analysis of mtDNA replication defects in yeast. *Methods.* 2010; 51(4):426–436. [PubMed: 20206271]
50. Stumpf JD, Bailey CM, Spell D, Stillwagon M, Anderson KS, Copeland WC. mip1 containing mutations associated with mitochondrial disease causes mutagenesis and depletion of mtDNA in *Saccharomyces cerevisiae*. *Hum Mol Genet.* 2010; 19(11):2123–2133. [PubMed: 20185557]
51. Baruffini E, Lodi T, Dallabona C, Puglisi A, Zeviani M, Ferrero I. Genetic and chemical rescue of the *Saccharomyces cerevisiae* phenotype induced by mitochondrial DNA polymerase mutations associated with progressive external ophthalmoplegia in humans. *Hum Mol Genet.* 2006; 15(19):2846–2855. [PubMed: 16940310]
52. Doudican NA, Song B, Shadel GS, Doetsch PW. Oxidative DNA damage causes mitochondrial genomic instability in *Saccharomyces cerevisiae*. *Mol Cell Biol.* 2005; 25(12):5196–5204. [PubMed: 15923634]
53. Szczepanowska K, Foury F. A cluster of pathogenic mutations in the 3'-5' exonuclease domain of DNA polymerase gamma defines a novel module coupling DNA synthesis and degradation. *Hum Mol Genet.* 2010; 19(18):3516–3529. [PubMed: 20601675]
54. Stuart GR, Santos JH, Strand MK, Van Houten B, Copeland WC. Mitochondrial and nuclear DNA defects in *Saccharomyces cerevisiae* with mutations in DNA polymerase gamma associated with progressive external ophthalmoplegia. *Hum Mol Genet.* 2006; 15(2):363–374. [PubMed: 16368709]
55. Baruffini E, Ferrero I, Foury F. Mitochondrial DNA defects in *Saccharomyces cerevisiae* caused by functional interactions between DNA polymerase gamma mutations associated with disease in human. *Biochim Biophys Acta.* 2007; 1772(11–12):1225–1235. [PubMed: 17980715]
56. Kramer R, Klingenberg M. Modulation of the reconstituted adenine nucleotide exchange by membrane potential. *Biochemistry.* 1980; 19(3):556–560. [PubMed: 6243950]

57. Block MR, Zaccai G, Lauquin GJ, Vignais PV. Small angle neutron scattering of the mitochondrial ADP/ATP carrier protein in detergent. *Biochem Biophys Res Commun.* 1982; 109(2):471–477. [PubMed: 6295398]
58. Hackenberg H, Klingenberg M. Molecular weight and hydrodynamic parameters of the adenosine 5'-diphosphate--adenosine 5'-triphosphate carrier in Triton X-100. *Biochemistry.* 1980; 19(3):548–555. [PubMed: 6243949]
59. Riccio P, Aquila H, Klingenberg M. Purification of the carboxy-atractylate binding protein from mitochondria. *FEBS Lett.* 1975; 56(1):133–138. [PubMed: 1171780]
60. Bamber L, Harding M, Butler PJ, Kunji ER. Yeast mitochondrial ADP/ATP carriers are monomeric in detergents. *Proc Natl Acad Sci U S A.* 2006; 103(44):16224–16229. [PubMed: 17056710]
61. Bamber L, Harding M, Monne M, Slotboom DJ, Kunji ER. The yeast mitochondrial ADP/ATP carrier functions as a monomer in mitochondrial membranes. *Proc Natl Acad Sci U S A.* 2007; 104(26):10830–10834. [PubMed: 17566106]
62. Bamber L, Slotboom DJ, Kunji ER. Yeast mitochondrial ADP/ATP carriers are monomeric in detergents as demonstrated by differential affinity purification. *J Mol Biol.* 2007; 371(2):388–395. [PubMed: 17572439]
63. Dolce V, Scarcia P, Iacopetta D, Palmieri F. A fourth ADP/ATP carrier isoform in man: identification, bacterial expression, functional characterization and tissue distribution. *FEBS Lett.* 2005; 579(3):633–637. [PubMed: 15670820]
64. Houldsworth J, Attardi G. Two distinct genes for ADP/ATP translocase are expressed at the mRNA level in adult human liver. *Proc Natl Acad Sci U S A.* 1988; 85(2):377–381. [PubMed: 2829183]
65. Stepien G, Torroni A, Chung AB, Hodge JA, Wallace DC. Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation. *J Biol Chem.* 1992; 267(21):14592–14597. [PubMed: 1378836]
66. Doerner A, Pauschinger M, Badorff A, Noutsias M, Giessen S, Schulze K, Bilger J, Rauch U, Schultheiss HP. Tissue-specific transcription pattern of the adenine nucleotide translocase isoforms in humans. *FEBS Lett.* 1997; 414(2):258–262. [PubMed: 9315697]
67. Lawson JE, Douglas MG. Separate genes encode functionally equivalent ADP/ATP carrier proteins in *Saccharomyces cerevisiae*. Isolation and analysis of AAC2. *J Biol Chem.* 1988; 263(29):14812–14818. [PubMed: 2844786]
68. Lawson JE, Gawaz M, Klingenberg M, Douglas MG. Structure-function studies of adenine nucleotide transport in mitochondria. I. Construction and genetic analysis of yeast mutants encoding the ADP/ATP carrier protein of mitochondria. *J Biol Chem.* 1990; 265(24):14195–14201. [PubMed: 2167308]
69. Napoli L, Bordoni A, Zeviani M, Hadjigeorgiou GM, Sciacco M, Tiranti V, Terentiu A, Moggio M, Papadimitriou A, Scarlato G, Comi GP. A novel missense adenine nucleotide translocator-1 gene mutation in a Greek adPEO family. *Neurology.* 2001; 57(12):2295–2298. [PubMed: 11756613]
70. Siciliano G, Tessa A, Petrini S, Mancuso M, Bruno C, Grieco GS, Malandrini A, DeFlorio L, Martini B, Federico A, Nappi G, Santorelli FM, Murri L. Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene. *Neuromuscul Disord.* 2003; 13(2):162–165. [PubMed: 12565915]
71. Kaukonen J, Juselius JK, Tiranti V, Kyttala A, Zeviani M, Comi GP, Keranen S, Peltonen L, Suomalainen A. Role of adenine nucleotide translocator 1 in mtDNA maintenance. *Science.* 2000; 289(5480):782–785. [PubMed: 10926541]
72. Deschauer M, Hudson G, Muller T, Taylor RW, Chinnery PF, Zierz S. A novel ANT1 gene mutation with probable germline mosaicism in autosomal dominant progressive external ophthalmoplegia. *Neuromuscul Disord.* 2005; 15(4):311–315. [PubMed: 15792871]
73. Komaki H, Fukazawa T, Houzen H, Yoshida K, Nonaka I, Goto Y. A novel D104G mutation in the adenine nucleotide translocator 1 gene in autosomal dominant progressive external ophthalmoplegia patients with mitochondrial DNA with multiple deletions. *Ann Neurol.* 2002; 51(5):645–648. [PubMed: 12112115]

74. Palmieri L, Alberio S, Pisano I, Lodi T, Meznaric-Petrusa M, Zidar J, Santoro A, Scarcia P, Fontanesi F, Lamantea E, Ferrero I, Zeviani M. Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy. *Hum Mol Genet.* 2005; 14(20):3079–3088. [PubMed: 16155110]
75. Fontanesi F, Palmieri L, Scarcia P, Lodi T, Donnini C, Limongelli A, Tiranti V, Zeviani M, Ferrero I, Viola AM. Mutations in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in *Saccharomyces cerevisiae* and affect mitochondrial DNA stability. *Hum Mol Genet.* 2004; 13(9):923–934. [PubMed: 15016764]
76. Arnold S, Kadenbach B. The intramitochondrial ATP/ADP-ratio controls cytochrome c oxidase activity allosterically. *FEBS Lett.* 1999; 443(2):105–108. [PubMed: 9989584]
77. Brown GC. Control of respiration and ATP synthesis in mammalian mitochondria and cells. *Biochem J.* 1992; 284(Pt 1):1–13. [PubMed: 1599389]
78. Wang X, Salinas K, Zuo X, Kucejova B, Chen XJ. Dominant membrane uncoupling by mutant adenine nucleotide translocase in mitochondrial diseases. *Hum Mol Genet.* 2008; 17(24):4036–4044. [PubMed: 18809618]
79. Chen XJ. Induction of an unregulated channel by mutations in adenine nucleotide translocase suggests an explanation for human ophthalmoplegia. *Hum Mol Genet.* 2002; 11(16):1835–1843. [PubMed: 12140186]
80. Kovacova V, Irmelerova J, Kovac L. Oxidative phosphorylation in yeast. IV. Combination of a nuclear mutation affecting oxidative phosphorylation with cytoplasmic mutation to respiratory deficiency. *Biochim Biophys Acta.* 1968; 162(2):157–163. [PubMed: 5682847]
81. Dupont CH, Mazat JP, Guerin B. The role of adenine nucleotide translocation in the energization of the inner membrane of mitochondria isolated from rho + and rho degree strains of *Saccharomyces cerevisiae*. *Biochem Biophys Res Commun.* 1985; 132(3):1116–1123. [PubMed: 3907630]
82. Weiher H, Noda T, Gray DA, Sharpe AH, Jaenisch R. Transgenic mouse model of kidney disease: insertional inactivation of ubiquitously expressed gene leads to nephrotic syndrome. *Cell.* 1990; 62(3):425–434. [PubMed: 1696177]
83. Zwacka RM, Reuter A, Pfaff E, Moll J, Gorgas K, Karasawa M, Weiher H. The glomerulosclerosis gene *Mpv17* encodes a peroxisomal protein producing reactive oxygen species. *EMBO J.* 1994; 13(21):5129–5134. [PubMed: 7957077]
84. Trott A, Morano KA. SYM1 is the stress-induced *Saccharomyces cerevisiae* ortholog of the mammalian kidney disease gene *Mpv17* and is required for ethanol metabolism and tolerance during heat shock. *Eukaryot Cell.* 2004; 3(3):620–631. [PubMed: 15189984]
85. Spinazzola A, Viscomi C, Fernandez-Vizarra E, Carrara F, D'Adamo P, Calvo S, Marsano RM, Donnini C, Weiher H, Strisciuglio P, Parini R, Sarzi E, Chan A, DiMauro S, Rotig A, Gasparini P, Ferrero I, Mootha VK, Tiranti V, Zeviani M. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. *Nat Genet.* 2006; 38(5):570–575. [PubMed: 16582910]
86. Spinazzola A, Santer R, Akman OH, Tsiakas K, Schaefer H, Ding X, Karadimas CL, Shanske S, Ganesh J, Di Mauro S, Zeviani M. Hepatocerebral form of mitochondrial DNA depletion syndrome: novel MPV17 mutations. *Arch Neurol.* 2008; 65(8):1108–1113. [PubMed: 18695062]
87. Karadimas CL, Vu TH, Holve SA, Chronopoulou P, Quinzii C, Johnsen SD, Kurth J, Eggers E, Palenzuela L, Tanji K, Bonilla E, De Vivo DC, DiMauro S, Hirano M. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. *Am J Hum Genet.* 2006; 79(3):544–548. [PubMed: 16909392]
88. Wong LJ, Brunetti-Pierri N, Zhang Q, Yazigi N, Bove KE, Dahms BB, Puchowicz MA, Gonzalez-Gomez I, Schmitt ES, Truong CK, Hoppel CL, Chou PC, Wang J, Baldwin EE, Adams D, Leslie N, Boles RG, Kerr DS, Craigen WJ. Mutations in the MPV17 gene are responsible for rapidly progressive liver failure in infancy. *Hepatology.* 2007; 46(4):1218–1227. [PubMed: 17694548]
89. Navarro-Sastre A, Martin-Hernandez E, Campos Y, Quintana E, Medina E, de Las Heras RS, Lluch M, Munoz A, del Hoyo P, Martin R, Gort L, Briones P, Ribes A. Lethal hepatopathy and leukodystrophy caused by a novel mutation in MPV17 gene: description of an alternative MPV17 spliced form. *Mol Genet Metab.* 2008; 94(2):234–239. [PubMed: 18329934]

90. Viscomi C, Spinazzola A, Maggioni M, Fernandez-Vizarra E, Massa V, Pagano C, Vettor R, Mora M, Zeviani M. Early-onset liver mtDNA depletion and late-onset proteinuric nephropathy in Mpv17 knockout mice. *Hum Mol Genet.* 2009; 18(1):12–26. [PubMed: 18818194]
91. Dallabona C, Marsano RM, Arzuffi P, Ghezzi D, Mancini P, Zeviani M, Ferrero I, Donnini C. Sym1, the yeast ortholog of the MPV17 human disease protein, is a stress-induced bioenergetic and morphogenetic mitochondrial modulator. *Hum Mol Genet.* 2010; 19(6):1098–1107. [PubMed: 20042463]
92. Xu N, Thorsness MK, Thorsness PE. Mitochondrial DNA impacts the morphology of mitochondrial compartments. *Gene.* 2005; 354:37–42. [PubMed: 15894435]
93. Hermann GJ, Thatcher JW, Mills JP, Hales KG, Fuller MT, Nunnari J, Shaw JM. Mitochondrial fusion in yeast requires the transmembrane GTPase Fzo1p. *J Cell Biol.* 1998; 143(2):359–373. [PubMed: 9786948]
94. Shepard KA, Yaffe MP. The yeast dynamin-like protein, Mgm1p, functions on the mitochondrial outer membrane to mediate mitochondrial inheritance. *J Cell Biol.* 1999; 144(4):711–720. [PubMed: 10037792]
95. Contamine V, Picard M. Maintenance and integrity of the mitochondrial genome: a plethora of nuclear genes in the budding yeast. *Microbiol Mol Biol Rev.* 2000; 64(2):281–315. [PubMed: 10839818]
96. Trotter PJ, Adamson AL, Ghrist AC, Rowe L, Scott LR, Sherman MP, Stites NC, Sun Y, Tawiah-Boateng MA, Tibbetts AS, Wadington MC, West AC. Mitochondrial transporters involved in oleic acid utilization and glutamate metabolism in yeast. *Arch Biochem Biophys.* 2005; 442(1):21–32. [PubMed: 16140254]
97. Palmieri L, Agrimi G, Runswick MJ, Fearnley IM, Palmieri F, Walker JE. Identification in *Saccharomyces cerevisiae* of two isoforms of a novel mitochondrial transporter for 2-oxoadipate and 2-oxoglutarate. *J Biol Chem.* 2001; 276(3):1916–1922. [PubMed: 11013234]
98. Parini R, Furlan F, Notarangelo L, Spinazzola A, Uziel G, Strisciuglio P, Concolino D, Corbetta C, Nebbia G, Menni F, Rossi G, Maggioni M, Zeviani M. Glucose metabolism and diet-based prevention of liver dysfunction in MPV17 mutant patients. *J Hepatol.* 2009; 50(1):215–221. [PubMed: 19012992]
99. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, Walford GA, Sugiana C, Boneh A, Chen WK, Hill DE, Vidal M, Evans JG, Thorburn DR, Carr SA, Mootha VK. A mitochondrial protein compendium elucidates complex I disease biology. *Cell.* 2008; 134(1):112–123. [PubMed: 18614015]
100. Chacinska A, Koehler CM, Milenkovic D, Lithgow T, Pfanner N. Importing mitochondrial proteins: machineries and mechanisms. *Cell.* 2009; 138(4):628–644. [PubMed: 19703392]
101. Becker T, Wenz LS, Kruger V, Lehmann W, Muller JM, Goroncy L, Zufall N, Lithgow T, Guiard B, Chacinska A, Wagner R, Meisinger C, Pfanner N. The mitochondrial import protein Mim1 promotes biogenesis of multispinning outer membrane proteins. *J Cell Biol.* 2011; 194(3):387–395. [PubMed: 21825073]
102. Papic D, Krumpe K, Dukanovic J, Dimmer KS, Rapaport D. Multispan mitochondrial outer membrane protein Ugo1 follows a unique Mim1-dependent import pathway. *J Cell Biol.* 2011; 194(3):397–405. [PubMed: 21825074]
103. Endo T, Yamano K, Kawano S. Structural basis for the disulfide relay system in the mitochondrial intermembrane space. *Antioxid Redox Signal.* 13(9):1359–1373. [PubMed: 20136511]
104. Hell K. The Erv1-Mia40 disulfide relay system in the intermembrane space of mitochondria. *Biochim Biophys Acta.* 2008; 1783(4):601–609. [PubMed: 18179776]
105. Koehler CM, Tienison HL. Redox regulation of protein folding in the mitochondrial intermembrane space. *Biochim Biophys Acta.* 2009; 1793(1):139–145. [PubMed: 18761382]
106. Riemer J, Fischer M, Herrmann JM. Oxidation-driven protein import into mitochondria: Insights and blind spots. *Biochim Biophys Acta.* 1808(3):981–989. [PubMed: 20537978]
107. Di Fonzo A, Ronchi D, Lodi T, Fassone E, Tigano M, Lamperti C, Corti S, Bordoni A, Fortunato F, Nizzardo M, Napoli L, Donadoni C, Salani S, Saladino F, Moggio M, Bresolin N, Ferrero I, Comi GP. The mitochondrial disulfide relay system protein GFER is mutated in autosomal-

- recessive myopathy with cataract and combined respiratory-chain deficiency. *Am J Hum Genet.* 2009; 84(5):594–604. [PubMed: 19409522]
108. Bien M, Longen S, Wagener N, Chwalla I, Herrmann JM, Riemer J. Mitochondrial disulfide bond formation is driven by intersubunit electron transfer in Erv1 and proofread by glutathione. *Mol Cell.* 2010; 37(4):516–528. [PubMed: 20188670]
 109. Bihlmaier K, Mesecke N, Terziyska N, Bien M, Hell K, Herrmann JM. The disulfide relay system of mitochondria is connected to the respiratory chain. *J Cell Biol.* 2007; 179(3):389–395. [PubMed: 17967948]
 110. Chacinska A, Pfannschmidt S, Wiedemann N, Kozjak V, Sanjuan Szklarz LK, Schulze-Specking A, Truscott KN, Guiard B, Meisinger C, Pfanner N. Essential role of Mia40 in import and assembly of mitochondrial intermembrane space proteins. *EMBO J.* 2004; 23(19):3735–3746. [PubMed: 15359280]
 111. Curran SP, Leuenberger D, Leverich EP, Hwang DK, Beverly KN, Koehler CM. The role of Hot13p and redox chemistry in the mitochondrial TIM22 import pathway. *J Biol Chem.* 2004; 279(42):43744–43751. [PubMed: 15294910]
 112. Dabir DV, Leverich EP, Kim SK, Tsai FD, Hirasawa M, Knaff DB, Koehler CM. A role for cytochrome c and cytochrome c peroxidase in electron shuttling from Erv1. *EMBO J.* 2007; 26(23):4801–4811. [PubMed: 17972915]
 113. Grumbt B, Stroobant V, Terziyska N, Israel L, Hell K. Functional characterization of Mia40p, the central component of the disulfide relay system of the mitochondrial intermembrane space. *J Biol Chem.* 2007; 282(52):37461–37470. [PubMed: 17959605]
 114. Hofmann S, Rothbauer U, Muhlenbein N, Baiker K, Hell K, Bauer MF. Functional and mutational characterization of human MIA40 acting during import into the mitochondrial intermembrane space. *J Mol Biol.* 2005; 353(3):517–528. [PubMed: 16185709]
 115. Kawano S, Yamano K, Naoe M, Momose T, Terao K, Nishikawa S, Watanabe N, Endo T. Structural basis of yeast Tim40/Mia40 as an oxidative translocator in the mitochondrial intermembrane space. *Proc Natl Acad Sci U S A.* 2009; 106(34):14403–14407. [PubMed: 19667201]
 116. Mesecke N, Bihlmaier K, Grumbt B, Longen S, Terziyska N, Hell K, Herrmann JM. The zinc-binding protein Hot13 promotes oxidation of the mitochondrial import receptor Mia40. *EMBO Rep.* 2008; 9(11):1107–1113. [PubMed: 18787558]
 117. Mesecke N, Terziyska N, Kozany C, Baumann F, Neupert W, Hell K, Herrmann JM. A disulfide relay system in the intermembrane space of mitochondria that mediates protein import. *Cell.* 2005; 121(7):1059–1069. [PubMed: 15989955]
 118. Milenkovic D, Gabriel K, Guiard B, Schulze-Specking A, Pfanner N, Chacinska A. Biogenesis of the essential Tim9-Tim10 chaperone complex of mitochondria: site-specific recognition of cysteine residues by the intermembrane space receptor Mia40. *J Biol Chem.* 2007; 282(31):22472–22480. [PubMed: 17553782]
 119. Muller JM, Milenkovic D, Guiard B, Pfanner N, Chacinska A. Precursor oxidation by Mia40 and Erv1 promotes vectorial transport of proteins into the mitochondrial intermembrane space. *Mol Biol Cell.* 2008; 19(1):226–236. [PubMed: 17978092]
 120. Reddehase S, Grumbt B, Neupert W, Hell K. The disulfide relay system of mitochondria is required for the biogenesis of mitochondrial Ccs1 and Sod1. *J Mol Biol.* 2009; 385(2):331–338. [PubMed: 19010334]
 121. Stojanovski D, Milenkovic D, Muller JM, Gabriel K, Schulze-Specking A, Baker MJ, Ryan MT, Guiard B, Pfanner N, Chacinska A. Mitochondrial protein import: precursor oxidation in a ternary complex with disulfide carrier and sulfhydryl oxidase. *J Cell Biol.* 2008; 183(2):195–202. [PubMed: 18852299]
 122. Terziyska N, Grumbt B, Bien M, Neupert W, Herrmann JM, Hell K. The sulfhydryl oxidase Erv1 is a substrate of the Mia40-dependent protein translocation pathway. *FEBS Lett.* 2007; 581(6):1098–1102. [PubMed: 17336303]
 123. Terziyska N, Grumbt B, Kozany C, Hell K. Structural and functional roles of the conserved cysteine residues of the redox-regulated import receptor Mia40 in the intermembrane space of mitochondria. *J Biol Chem.* 2009; 284(3):1353–1363. [PubMed: 19011240]

124. Tienison HL, Dabir DV, Neal SE, Loo R, Hasson SA, Boontheung P, Kim SK, Loo JA, Koehler CM. Reconstitution of the mia40-erv1 oxidative folding pathway for the small tim proteins. *Mol Biol Cell*. 2009; 20(15):3481–3490. [PubMed: 19477928]
125. Webb CT, Gorman MA, Lazarou M, Ryan MT, Gulbis JM. Crystal structure of the mitochondrial chaperone TIM9.10 reveals a six-bladed alpha-propeller. *Mol Cell*. 2006; 21(1):123–133. [PubMed: 16387659]
126. Koehler CM. The small Tim proteins and the twin Cx3C motif. *Trends Biochem Sci*. 2004; 29(1):1–4. [PubMed: 14729324]
127. Koehler CM, Jarosch E, Tokatlidis K, Schmid K, Schweyen RJ, Schatz G. Import of mitochondrial carriers mediated by essential proteins of the intermembrane space. *Science*. 1998; 279(5349):369–373. [PubMed: 9430585]
128. Koehler CM, Merchant S, Oppliger W, Schmid K, Jarosch E, Dolfini L, Junne T, Schatz G, Tokatlidis K. Tim9p, an essential partner subunit of Tim10p for the import of mitochondrial carrier proteins. *EMBO J*. 1998; 17(22):6477–6486. [PubMed: 9822593]
129. Davis AJ, Sepuri NB, Holder J, Johnson AE, Jensen RE. Two intermembrane space TIM complexes interact with different domains of Tim23p during its import into mitochondria. *J Cell Biol*. 2000; 150(6):1271–1282. [PubMed: 10995434]
130. Kerscher O, Holder J, Srinivasan M, Leung RS, Jensen RE. The Tim54p-Tim22p complex mediates insertion of proteins into the mitochondrial inner membrane. *J Cell Biol*. 1997; 139(7):1663–1675. [PubMed: 9412462]
131. Kovermann P, Truscott KN, Guiard B, Rehling P, Sepuri NB, Muller H, Jensen RE, Wagner R, Pfanner N. Tim22, the essential core of the mitochondrial protein insertion complex, forms a voltage-activated and signal-gated channel. *Mol Cell*. 2002; 9(2):363–373. [PubMed: 11864609]
132. Leuenberger D, Bally NA, Schatz G, Koehler CM. Different import pathways through the mitochondrial intermembrane space for inner membrane proteins. *EMBO J*. 1999; 18(17):4816–4822. [PubMed: 10469659]
133. Paschen SA, Rothbauer U, Kaldi K, Bauer MF, Neupert W, Brunner M. The role of the TIM8-13 complex in the import of Tim23 into mitochondria. *EMBO J*. 2000; 19(23):6392–6400. [PubMed: 11101512]
134. Koehler CM, Leuenberger D, Merchant S, Renold A, Junne T, Schatz G. Human deafness dystonia syndrome is a mitochondrial disease. *Proc Natl Acad Sci U S A*. 1999; 96(5):2141–2146. [PubMed: 10051608]
135. Roesch K, Curran SP, Tranebjaerg L, Koehler CM. Human deafness dystonia syndrome is caused by a defect in assembly of the DDP1/TIMM8a-TIMM13 complex. *Hum Mol Genet*. 2002; 11(5):477–486. [PubMed: 11875042]
136. Rothbauer U, Hofmann S, Muhlenbein N, Paschen SA, Gerbitz KD, Neupert W, Brunner M, Bauer MF. Role of the deafness dystonia peptide 1 (DDP1) in import of human Tim23 into the inner membrane of mitochondria. *J Biol Chem*. 2001; 276(40):37327–37334. [PubMed: 11489896]
137. Aguirre LA, del Castillo I, Macaya A, Meda C, Villamar M, Moreno-Pelayo MA, Moreno F. A novel mutation in the gene encoding TIMM8a, a component of the mitochondrial protein translocase complexes, in a Spanish familial case of deafness-dystonia (Mohr-Tranebjaerg) syndrome. *Am J Med Genet A*. 2006; 140(4):392–397. [PubMed: 16411215]
138. Jin H, May M, Tranebjaerg L, Kendall E, Fontan G, Jackson J, Subramony SH, Arena F, Lubs H, Smith S, Stevenson R, Schwartz C, Vetrie D. A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. *Nat Genet*. 1996; 14(2):177–180. [PubMed: 8841189]
139. Swerdlow RH, Wooten GF. A novel deafness/dystonia peptide gene mutation that causes dystonia in female carriers of Mohr-Tranebjaerg syndrome. *Ann Neurol*. 2001; 50(4):537–540. [PubMed: 11601506]
140. Ujike H, Tanabe Y, Takehisa Y, Hayabara T, Kuroda S. A family with X-linked dystonia-deafness syndrome with a novel mutation of the DDP gene. *Arch Neurol*. 2001; 58(6):1004–1007. [PubMed: 11405816]

141. Ezquerra M, Campdelacreu J, Munoz E, Tolosa E, Marti MJ. A novel intronic mutation in the DDP1 gene in a family with X-linked dystonia-deafness syndrome. *Arch Neurol.* 2005; 62(2): 306–308. [PubMed: 15710860]
142. Tranebjaerg L, Hamel BC, Gabreels FJ, Renier WO, Van Ghelue M. A de novo missense mutation in a critical domain of the X-linked DDP gene causes the typical deafness-dystonia-optic atrophy syndrome. *Eur J Hum Genet.* 2000; 8(6):464–467. [PubMed: 10878669]
143. Binder J, Hofmann S, Kreisel S, Wohrle JC, Bazner H, Krauss JK, Hennerici MG, Bauer MF. Clinical and molecular findings in a patient with a novel mutation in the deafness-dystonia peptide (DDP1) gene. *Brain.* 2003; 126(Pt 8):1814–1820. [PubMed: 12805099]
144. Hofmann S, Rothbauer U, Muhlenbein N, Neupert W, Gerbitz KD, Brunner M, Bauer MF. The C66W mutation in the deafness dystonia peptide 1 (DDP1) affects the formation of functional DDP1.TIM13 complexes in the mitochondrial intermembrane space. *J Biol Chem.* 2002; 277(26):23287–23293. [PubMed: 11956200]
145. Westermann B. Mitochondrial dynamics in model organisms: what yeasts, worms and flies have taught us about fusion and fission of mitochondria. *Semin Cell Dev Biol.* 2010; 21(6):542–549. [PubMed: 20006727]
146. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. *Cell.* 2006; 125(7):1241–1252. [PubMed: 16814712]
147. Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, Stiles L, Haigh SE, Katz S, Las G, Alroy J, Wu M, Py BF, Yuan J, Deeney JT, Corkey BE, Shirihai OS. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. *EMBO J.* 2008; 27(2): 433–446. [PubMed: 18200046]
148. Suen DF, Norris KL, Youle RJ. Mitochondrial dynamics and apoptosis. *Genes Dev.* 2008; 22(12): 1577–1590. [PubMed: 18559474]
149. Ishihara N, Eura Y, Mihara K. Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. *J Cell Sci.* 2004; 117(Pt 26):6535–6546. [PubMed: 15572413]
150. Koshiba T, Detmer SA, Kaiser JT, Chen H, McCaffery JM, Chan DC. Structural basis of mitochondrial tethering by mitofusin complexes. *Science.* 2004; 305(5685):858–862. [PubMed: 15297672]
151. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *J Cell Biol.* 2003; 160(2):189–200. [PubMed: 12527753]
152. Cipolat S, Martins de Brito O, Dal Zilio B, Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. *Proc Natl Acad Sci U S A.* 2004; 101(45):15927–15932. [PubMed: 15509649]
153. Detmer SA, Chan DC. Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations. *J Cell Biol.* 2007; 176(4):405–414. [PubMed: 17296794]
154. Griffin EE, Chan DC. Domain interactions within Fzo1 oligomers are essential for mitochondrial fusion. *J Biol Chem.* 2006; 281(24):16599–16606. [PubMed: 16624808]
155. Meeusen S, McCaffery JM, Nunnari J. Mitochondrial fusion intermediates revealed *in vitro*. *Science.* 2004; 305(5691):1747–1752. [PubMed: 15297626]
156. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schroder JM, Vance JM. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. *Nat Genet.* 2004; 36(5):449–451. [PubMed: 15064763]
157. Ouvrier R, Grew S. Mechanisms of disease and clinical features of mutations of the gene for mitofusin 2: an important cause of hereditary peripheral neuropathy with striking clinical variability in children and adults. *Dev Med Child Neurol.* 2010; 52(4):328–330. [PubMed: 20163430]
158. Cartoni R, Martinou JC. Role of mitofusin 2 mutations in the physiopathology of Charcot-Marie-Tooth disease type 2A. *Exp Neurol.* 2009; 218(2):268–273. [PubMed: 19427854]

159. Amiott EA, Cohen MM, Saint-Georges Y, Weissman AM, Shaw JM. A mutation associated with CMT2A neuropathy causes defects in Fzo1 GTP hydrolysis, ubiquitylation, and protein turnover. *Mol Biol Cell*. 2009; 20(23):5026–5035. [PubMed: 19812251]
160. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, Pelloquin L, Grosgeorge J, Turc-Carel C, Perret E, Astarie-Dequeker C, Lasquellec L, Arnaud B, Ducommun B, Kaplan J, Hamel CP. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. *Nat Genet*. 2000; 26(2):207–210. [PubMed: 11017079]
161. Meeusen S, DeVay R, Block J, Cassidy-Stone A, Wayson S, McCaffery JM, Nunnari J. Mitochondrial inner-membrane fusion and crista maintenance requires the dynamin-related GTPase Mgm1. *Cell*. 2006; 127(2):383–395. [PubMed: 17055438]
162. van der Bliek AM. Functional diversity in the dynamin family. *Trends Cell Biol*. 1999; 9(3):96–102. [PubMed: 10201074]
163. Smirnova E, Shurland DL, Newman-Smith ED, Pishvae B, van der Bliek AM. A model for dynamin self-assembly based on binding between three different protein domains. *J Biol Chem*. 1999; 274(21):14942–14947. [PubMed: 10329695]
164. Sesaki H, Southard SM, Yaffe MP, Jensen RE. Mgm1p, a dynamin-related GTPase, is essential for fusion of the mitochondrial outer membrane. *Mol Biol Cell*. 2003; 14(6):2342–2356. [PubMed: 12808034]
165. Wong ED, Wagner JA, Gorsich SW, McCaffery JM, Shaw JM, Nunnari J. The dynamin-related GTPase, Mgm1p, is an intermembrane space protein required for maintenance of fusion competent mitochondria. *J Cell Biol*. 2000; 151(2):341–352. [PubMed: 11038181]
166. Wong ED, Wagner JA, Scott SV, Okreglak V, Holewinski TJ, Cassidy-Stone A, Nunnari J. The intramitochondrial dynamin-related GTPase, Mgm1p, is a component of a protein complex that mediates mitochondrial fusion. *J Cell Biol*. 2003; 160(3):303–311. [PubMed: 12566426]
167. Delettre C, Griffoin JM, Kaplan J, Dollfus H, Lorenz B, Faivre L, Lenaers G, Belenguer P, Hamel CP. Mutation spectrum and splicing variants in the OPA1 gene. *Hum Genet*. 2001; 109(6):584–591. [PubMed: 11810270]
168. Duvezin-Caubet S, Jagasia R, Wagener J, Hofmann S, Trifunovic A, Hansson A, Chomyn A, Bauer MF, Attardi G, Larsson NG, Neupert W, Reichert AS. Proteolytic processing of OPA1 links mitochondrial dysfunction to alterations in mitochondrial morphology. *J Biol Chem*. 2006; 281(49):37972–37979. [PubMed: 17003040]
169. Duvezin-Caubet S, Koppen M, Wagener J, Zick M, Israel L, Bernacchia A, Jagasia R, Rugarli EI, Imhof A, Neupert W, Langer T, Reichert AS. OPA1 processing reconstituted in yeast depends on the subunit composition of the m-AAA protease in mitochondria. *Mol Biol Cell*. 2007; 18(9):3582–3590. [PubMed: 17615298]
170. Griparic L, Kanazawa T, van der Bliek AM. Regulation of the mitochondrial dynamin-like protein Opa1 by proteolytic cleavage. *J Cell Biol*. 2007; 178(5):757–764. [PubMed: 17709430]
171. Song Z, Chen H, Fiket M, Alexander C, Chan DC. OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L. *J Cell Biol*. 2007; 178(5):749–755. [PubMed: 17709429]
172. Ehses S, Raschke I, Mancuso G, Bernacchia A, Geimer S, Tondera D, Martinou JC, Westermann B, Rugarli EI, Langer T. Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. *J Cell Biol*. 2009; 187(7):1023–1036. [PubMed: 20038678]
173. Head B, Griparic L, Amiri M, Gandre-Babbe S, van der Bliek AM. Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. *J Cell Biol*. 2009; 187(7):959–966. [PubMed: 20038677]
174. Herlan M, Vogel F, Bornhove C, Neupert W, Reichert AS. Processing of Mgm1 by the rhomboid-type protease Pcp1 is required for maintenance of mitochondrial morphology and of mitochondrial DNA. *J Biol Chem*. 2003; 278(30):27781–27788. [PubMed: 12707284]
175. McQuibban GA, Saurya S, Freeman M. Mitochondrial membrane remodelling regulated by a conserved rhomboid protease. *Nature*. 2003; 423(6939):537–541. [PubMed: 12774122]
176. DeVay RM, Dominguez-Ramirez L, Lackner LL, Hoppins S, Stahlberg H, Nunnari J. Coassembly of Mgm1 isoforms requires cardiolipin and mediates mitochondrial inner membrane fusion. *J Cell Biol*. 2009; 186(6):793–803. [PubMed: 19752025]

177. Zick M, Duvezin-Caubet S, Schafer A, Vogel F, Neupert W, Reichert AS. Distinct roles of the two isoforms of the dynamin-like GTPase Mgm1 in mitochondrial fusion. *FEBS Lett.* 2009; 583(13):2237–2243. [PubMed: 19505460]
178. Votruba M, Moore AT, Bhattacharya SS. Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy. *J Med Genet.* 1998; 35(10):793–800. [PubMed: 9783700]
179. Ferre M, Amati-Bonneau P, Tourmen Y, Malthiery Y, Reynier P. eOPA1: an online database for OPA1 mutations. *Hum Mutat.* 2005; 25(5):423–428. [PubMed: 15832306]
180. Amutha B, Gordon DM, Gu Y, Pain D. A novel role of Mgm1p, a dynamin-related GTPase, in ATP synthase assembly and cristae formation/maintenance. *Biochem J.* 2004; 381(Pt 1):19–23. [PubMed: 15125685]
181. Arnold I, Pfeiffer K, Neupert W, Stuart RA, Schagger H. Yeast mitochondrial F1F0-ATP synthase exists as a dimer: identification of three dimer-specific subunits. *EMBO J.* 1998; 17(24):7170–7178. [PubMed: 9857174]
182. Paumard P, Vaillier J, Couлары B, Schaeffer J, Soubannier V, Mueller DM, Brethes D, di Rago JP, Velours J. The ATP synthase is involved in generating mitochondrial cristae morphology. *EMBO J.* 2002; 21(3):221–230. [PubMed: 11823415]
183. Rabl R, Soubannier V, Scholz R, Vogel F, Mendl N, Vasiljev-Neumeyer A, Korner C, Jagasia R, Keil T, Baumeister W, Cyrklaff M, Neupert W, Reichert AS. Formation of cristae and crista junctions in mitochondria depends on antagonism between Fcjl and Su e/g. *J Cell Biol.* 2009; 185(6):1047–1063. [PubMed: 19528297]
184. Strauss M, Hofhaus G, Schroder RR, Kuhlbrandt W. Dimer ribbons of ATP synthase shape the inner mitochondrial membrane. *EMBO J.* 2008; 27(7):1154–1160. [PubMed: 18323778]
185. Chen H, Chan DC. Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases. *Hum Mol Genet.* 2009; 18(R2):R169–R176. [PubMed: 19808793]
186. Misko A, Jiang S, Węgorzewska I, Milbrandt J, Baloh RH. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. *J Neurosci.* 2010; 30(12):4232–4240. [PubMed: 20335458]
187. Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. *Nat Rev Neurosci.* 2008; 9(7):505–518. [PubMed: 18568013]
188. Smirnova E, Shurland DL, Ryazantsev SN, van der Bliek AM. A human dynamin-related protein controls the distribution of mitochondria. *J Cell Biol.* 1998; 143(2):351–358. [PubMed: 9786947]
189. Otsuga D, Keegan BR, Brisch E, Thatcher JW, Hermann GJ, Bleazard W, Shaw JM. The dynamin-related GTPase, Dnm1p, controls mitochondrial morphology in yeast. *J Cell Biol.* 1998; 143(2):333–349. [PubMed: 9786946]
190. Bleazard W, McCaffery JM, King EJ, Bale S, Mozdy A, Tieu Q, Nunnari J, Shaw JM. The dynamin-related GTPase Dnm1 regulates mitochondrial fission in yeast. *Nat Cell Biol.* 1999; 1(5):298–304. [PubMed: 10559943]
191. Fukushima NH, Brisch E, Keegan BR, Bleazard W, Shaw JM. The GTPase effector domain sequence of the Dnm1p GTPase regulates self-assembly and controls a rate-limiting step in mitochondrial fission. *Mol Biol Cell.* 2001; 12(9):2756–2766. [PubMed: 11553714]
192. Mears JA, Lackner LL, Fang S, Ingerman E, Nunnari J, Hinshaw JE. Conformational changes in Dnm1 support a contractile mechanism for mitochondrial fission. *Nat Struct Mol Biol.* 2011; 18(1):20–26. [PubMed: 21170049]
193. Ingerman E, Perkins EM, Marino M, Mears JA, McCaffery JM, Hinshaw JE, Nunnari J. Dnm1 forms spirals that are structurally tailored to fit mitochondria. *J Cell Biol.* 2005; 170(7):1021–1027. [PubMed: 16186251]
194. Waterham HR, Koster J, van Roermund CW, Mooyer PA, Wanders RJ, Leonard JV. A lethal defect of mitochondrial and peroxisomal fission. *N Engl J Med.* 2007; 356(17):1736–1741. [PubMed: 17460227]
195. Bhar D, Karren MA, Babst M, Shaw JM. Dimeric Dnm1-G385D interacts with Mdv1 on mitochondria and can be stimulated to assemble into fission complexes containing Mdv1 and Fis1. *J Biol Chem.* 2006; 281(25):17312–17320. [PubMed: 16601120]

196. Naylor K, Ingerman E, Okreglak V, Marino M, Hinshaw JE, Nunnari J. Mdv1 interacts with assembled dnm1 to promote mitochondrial division. *J Biol Chem.* 2006; 281(4):2177–2183. [PubMed: 16272155]
197. Chang CR, Manlandro CM, Arnoult D, Stadler J, Posey AE, Hill RB, Blackstone C. A lethal de novo mutation in the middle domain of the dynamin-related GTPase Drp1 impairs higher order assembly and mitochondrial division. *J Biol Chem.* 2010; 285(42):32494–32503. [PubMed: 20696759]
198. Youle RJ, Narendra DP. Mechanisms of mitophagy. *Nat Rev Mol Cell Biol.* 2011; 12(1):9–14. [PubMed: 21179058]
199. Koppen M, Metodiev MD, Casari G, Rugarli EI, Langer T. Variable and tissue-specific subunit composition of mitochondrial m-AAA protease complexes linked to hereditary spastic paraplegia. *Mol Cell Biol.* 2007; 27(2):758–767. [PubMed: 17101804]
200. Koppen M, Langer T. Protein degradation within mitochondria: versatile activities of AAA proteases and other peptidases. *Crit Rev Biochem Mol Biol.* 2007; 42(3):221–242. [PubMed: 17562452]
201. Augustin S, Gerdes F, Lee S, Tsai FT, Langer T, Tatsuta T. An intersubunit signaling network coordinates ATP hydrolysis by m-AAA proteases. *Mol Cell.* 2009; 35(5):574–585. [PubMed: 19748354]
202. Bonn F, Pantakani K, Shoukier M, Langer T, Mannan AU. Functional evaluation of paraplegin mutations by a yeast complementation assay. *Hum Mutat.* 2010; 31(5):617–621. [PubMed: 20186691]
203. Paul MF, Tzagoloff A. Mutations in RCA1 and AFG3 inhibit F1-ATPase assembly in *Saccharomyces cerevisiae*. *FEBS Lett.* 1995; 373(1):66–70. [PubMed: 7589436]
204. Rep M, Nooy J, Guelin E, Grivell LA. Three genes for mitochondrial proteins suppress null-mutations in both Afg3 and Rca1 when over-expressed. *Curr Genet.* 1996; 30(3):206–211. [PubMed: 8753648]
205. Arlt H, Steglich G, Perryman R, Guiard B, Neupert W, Langer T. The formation of respiratory chain complexes in mitochondria is under the proteolytic control of the m-AAA protease. *EMBO J.* 1998; 17(16):4837–4847. [PubMed: 9707443]
206. Nolden M, Ehses S, Koppen M, Bernacchia A, Rugarli EI, Langer T. The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria. *Cell.* 2005; 123(2):277–289. [PubMed: 16239145]
207. Harding AE. Classification of the hereditary ataxias and paraplegias. *Lancet.* 1983; 1(8334):1151–1155. [PubMed: 6133167]
208. Fink JK. Advances in the hereditary spastic paraplegias. *Exp Neurol.* 2003; 184(Suppl 1):S106–S110. [PubMed: 14597333]
209. Casari G, De Fusco M, Ciarmatori S, Zeviani M, Mora M, Fernandez P, De Michele G, Filla A, Coccozza S, Marconi R, Durr A, Fontaine B, Ballabio A. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. *Cell.* 1998; 93(6):973–983. [PubMed: 9635427]
210. Cagnoli C, Mariotti C, Taroni F, Seri M, Brussino A, Michielotto C, Grisoli M, Di Bella D, Migone N, Gellera C, Di Donato S, Brusco A. SCA28, a novel form of autosomal dominant cerebellar ataxia on chromosome 18p11.22-q11.2. *Brain.* 2006; 129(Pt 1):235–242. [PubMed: 16251216]
211. Schols L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias clinical features, genetics, and pathogenesis. *Lancet Neurol.* 2004; 3(5):291–304. [PubMed: 15099544]
212. Di Bella D, Lazzaro F, Brusco A, Plumari M, Battaglia G, Pastore A, Finardi A, Cagnoli C, Tempia F, Frontali M, Veneziano L, Sacco T, Boda E, Brussino A, Bonn F, Castellotti B, Baratta S, Mariotti C, Gellera C, Fracasso V, Magri S, Langer T, Plevani P, Di Donato S, Muzi-Falconi M, Taroni F. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. *Nat Genet.* 2010; 42(4):313–321. [PubMed: 20208537]
213. Fernandez-Vizarra E, Tiranti V, Zeviani M. Assembly of the oxidative phosphorylation system in humans: what we have learned by studying its defects. *Biochim Biophys Acta.* 2009; 1793(1):200–211. [PubMed: 18620006]

214. Lemire BD, Oyedotun KS. The *Saccharomyces cerevisiae* mitochondrial succinate:ubiquinone oxidoreductase. *Biochim Biophys Acta*. 2002; 1553(1–2):102–116. [PubMed: 11803020]
215. Sun F, Huo X, Zhai Y, Wang A, Xu J, Su D, Bartlam M, Rao Z. Crystal structure of mitochondrial respiratory membrane protein complex II. *Cell*. 2005; 121(7):1043–1057. [PubMed: 15989954]
216. Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, Munnich A, Rotig A. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. *Nat Genet*. 1995; 11(2):144–149. [PubMed: 7550341]
217. Hensen EF, Bayley JP. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. *Fam Cancer*. 2010
218. Horvath R, Abicht A, Holinski-Feder E, Laner A, Gempel K, Prokisch H, Lochmuller H, Klopstock T, Jaksch M. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). *J Neurol Neurosurg Psychiatry*. 2006; 77(1):74–76. [PubMed: 16361598]
219. Levitas A, Muhammad E, Harel G, Saada A, Caspi VC, Manor E, Beck JC, Sheffield V, Parvari R. Familial neonatal isolated cardiomyopathy caused by a mutation in the flavoprotein subunit of succinate dehydrogenase. *Eur J Hum Genet*. 2010; 18(10):1160–1165. [PubMed: 20551992]
220. Parfait B, Chretien D, Rotig A, Marsac C, Munnich A, Rustin P. Compound heterozygous mutations in the flavoprotein gene of the respiratory chain complex II in a patient with Leigh syndrome. *Hum Genet*. 2000; 106(2):236–243. [PubMed: 10746566]
221. Van Coster R, Seneca S, Smet J, Van Hecke R, Gerlo E, Devreese B, Van Beeumen J, Leroy JG, De Meirleir L, Lissens W. Homozygous Gly555Glu mutation in the nuclear-encoded 70 kDa flavoprotein gene causes instability of the respiratory chain complex II. *Am J Med Genet A*. 2003; 120A(1):13–18. [PubMed: 12794685]
222. Dahl HH. Getting to the nucleus of mitochondrial disorders: identification of respiratory chain-enzyme genes causing Leigh syndrome. *Am J Hum Genet*. 1998; 63(6):1594–1597. [PubMed: 9837811]
223. Vanharanta S, Buchta M, McWhinney SR, Virta SK, Peczkowska M, Morrison CD, Lehtonen R, Januszewicz A, Jarvinen H, Juhola M, Mecklin JP, Pukkala E, Herva R, Kiuru M, Nupponen NN, Aaltonen LA, Neumann HP, Eng C. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. *Am J Hum Genet*. 2004; 74(1):153–159. [PubMed: 14685938]
224. van Schothorst EM, Beekman M, Torremans P, Kuipers-Dijkshoorn NJ, Wessels HW, Bardeol AF, van der Mey AG, van der Vijver MJ, van Ommen GJ, Devilee P, Cornelisse CJ. Paragangliomas of the head and neck region show complete loss of heterozygosity at 11q22–q23 in chief cells and the flow-sorted DNA aneuploid fraction. *Hum Pathol*. 1998; 29(10):1045–1049. [PubMed: 9781639]
225. Baysal BE. Clinical and molecular progress in hereditary paraganglioma. *J Med Genet*. 2008; 45(11):689–694. [PubMed: 18978332]
226. Ishii N, Fujii M, Hartman PS, Tsuda M, Yasuda K, Senoo-Matsuda N, Yanase S, Ayusawa D, Suzuki K. A mutation in succinate dehydrogenase cytochrome b causes oxidative stress and ageing in nematodes. *Nature*. 1998; 394(6694):694–697. [PubMed: 9716135]
227. Szeto SS, Reinke SN, Sykes BD, Lemire BD. Ubiquinone-binding site mutations in the *Saccharomyces cerevisiae* succinate dehydrogenase generate superoxide and lead to the accumulation of succinate. *J Biol Chem*. 2007; 282(37):27518–27526. [PubMed: 17636259]
228. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. *Oncogene*. 2006; 25(34):4675–4682. [PubMed: 16892081]
229. Burnichon N, Briere JJ, Libe R, Vescovo L, Riviere J, Tissier F, Jouanno E, Jeunemaitre X, Benit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, Gimenez-Roqueplo AP. SDHA is a tumor suppressor gene causing paraganglioma. *Hum Mol Genet*. 2010; 19(15):3011–3020. [PubMed: 20484225]

230. Guo J, Lemire BD. The ubiquinone-binding site of the *Saccharomyces cerevisiae* succinate-ubiquinone oxidoreductase is a source of superoxide. *J Biol Chem.* 2003; 278(48):47629–47635. [PubMed: 13129931]
231. Goffrini P, Ercolino T, Panizza E, Giache V, Cavone L, Chiarugi A, Dima V, Ferrero I, Mannelli M. Functional study in a yeast model of a novel succinate dehydrogenase subunit B gene germline missense mutation (C191Y) diagnosed in a patient affected by a glomus tumor. *Hum Mol Genet.* 2009; 18(10):1860–1868. [PubMed: 19261679]
232. Smith EH, Janknecht R, Maher LJ 3rd. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. *Hum Mol Genet.* 2007; 16(24):3136–3148. [PubMed: 17884808]
233. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF- α prolyl hydroxylase. *Cancer Cell.* 2005; 7(1):77–85. [PubMed: 15652751]
234. Hao HX, Khalimonchuk O, Schraders M, Dephoure N, Bayley JP, Kunst H, Devilee P, Cremers CW, Schiffman JD, Bentz BG, Gygi SP, Winge DR, Kremer H, Rutter J. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. *Science.* 2009; 325(5944):1139–1142. [PubMed: 19628817]
235. Brockmann K, Bjornstad A, Dechent P, Korenke CG, Smeitink J, Trijbels JM, Athanassopoulos S, Villagran R, Skjeldal OH, Wilichowski E, Frahm J, Hanefeld F. Succinate in dystrophic white matter: a proton magnetic resonance spectroscopy finding characteristic for complex II deficiency. *Ann Neurol.* 2002; 52(1):38–46. [PubMed: 12112045]
236. Bugiani M, Lamantea E, Invernizzi F, Moroni I, Bizzi A, Zeviani M, Uziel G. Effects of riboflavin in children with complex II deficiency. *Brain Dev.* 2006; 28(9):576–581. [PubMed: 16737791]
237. Ghezzi D, Goffrini P, Uziel G, Horvath R, Klopstock T, Lochmuller H, D'Adamo P, Gasparini P, Strom TM, Prokisch H, Invernizzi F, Ferrero I, Zeviani M. SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. *Nat Genet.* 2009; 41(6):654–656. [PubMed: 19465911]
238. Iwata S, Lee JW, Okada K, Lee JK, Iwata M, Rasmussen B, Link TA, Ramaswamy S, Jap BK. Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. *Science.* 1998; 281(5373):64–71. [PubMed: 9651245]
239. Hunte C, Koepke J, Lange C, Rossmannith T, Michel H. Structure at 2.3 Å resolution of the cytochrome bc(1) complex from the yeast *Saccharomyces cerevisiae* co-crystallized with an antibody Fv fragment. *Structure.* 2000; 8(6):669–684. [PubMed: 10873857]
240. Fisher N, Meunier B. Effects of mutations in mitochondrial cytochrome b in yeast and man. Deficiency, compensation and disease. *Eur J Biochem.* 2001; 268(5):1155–1162. [PubMed: 11231266]
241. Andreu AL, Bruno C, Hadjigeorgiou GM, Shanske S, DiMauro S. Polymorphic variants in the human mitochondrial cytochrome b gene. *Mol Genet Metab.* 1999; 67(1):49–52. [PubMed: 10329023]
242. Blakely EL, Mitchell AL, Fisher N, Meunier B, Nijtmans LG, Schaefer AM, Jackson MJ, Turnbull DM, Taylor RW. A mitochondrial cytochrome b mutation causing severe respiratory chain enzyme deficiency in humans and yeast. *FEBS J.* 2005; 272(14):3583–3592. [PubMed: 16008558]
243. Fisher N, Castleden CK, Bourges I, Brasseur G, Dujardin G, Meunier B. Human disease-related mutations in cytochrome b studied in yeast. *J Biol Chem.* 2004; 279(13):12951–12958. [PubMed: 14718526]
244. Wenz T, Hellwig P, MacMillan F, Meunier B, Hunte C. Probing the role of E272 in quinol oxidation of mitochondrial complex III. *Biochemistry.* 2006; 45(30):9042–9052. [PubMed: 16866349]
245. Fisher N, Bourges I, Hill P, Brasseur G, Meunier B. Disruption of the interaction between the Rieske iron-sulfur protein and cytochrome b in the yeast bc1 complex owing to a human disease-associated mutation within cytochrome b. *Eur J Biochem.* 2004; 271(7):1292–1298. [PubMed: 15030479]

246. Nobrega FG, Nobrega MP, Tzagoloff A. BCS1, a novel gene required for the expression of functional Rieske iron-sulfur protein in *Saccharomyces cerevisiae*. *EMBO J.* 1992; 11(11):3821–3829. [PubMed: 1327750]
247. Craciun CM, Hell K, Folsch H, Neupert W, Stuart RA. Bcs1p, an AAA-family member, is a chaperone for the assembly of the cytochrome bc(1) complex. *EMBO J.* 1999; 18(19):5226–5233. [PubMed: 10508156]
248. de Lonlay P, Valnot I, Barrientos A, Gorbatyuk M, Tzagoloff A, Taanman JW, Benayoun E, Chretien D, Kadhom N, Lombes A, de Baulny HO, Niaudet P, Munnich A, Rustin P, Rotig A. A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure. *Nat Genet.* 2001; 29(1):57–60. [PubMed: 11528392]
249. De Meirleir L, Seneca S, Damis E, Sepulchre B, Hoorens A, Gerlo E, Garcia Silva MT, Hernandez EM, Lissens W, Van Coster R. Clinical and diagnostic characteristics of complex III deficiency due to mutations in the BCS1L gene. *Am J Med Genet A.* 2003; 121A(2):126–131. [PubMed: 12910490]
250. Fernandez-Vizarra E, Bugiani M, Goffrini P, Carrara F, Farina L, Procopio E, Donati A, Uziel G, Ferrero I, Zeviani M. Impaired complex III assembly associated with BCS1L gene mutations in isolated mitochondrial encephalopathy. *Hum Mol Genet.* 2007; 16(10):1241–1252. [PubMed: 17403714]
251. Tuppen HA, Fehmi J, Czermin B, Goffrini P, Meloni F, Ferrero I, He L, Blakely EL, McFarland R, Horvath R, Turnbull DM, Taylor RW. Long-term survival of neonatal mitochondrial complex III deficiency associated with a novel BCS1L gene mutation. *Mol Genet Metab.* 2010; 100(4):345–348. [PubMed: 20472482]
252. Visapaa I, Fellman V, Vesa J, Dasvarma A, Hutton JL, Kumar V, Payne GS, Makarow M, Van Coster R, Taylor RW, Turnbull DM, Suomalainen A, Peltonen L. GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L. *Am J Hum Genet.* 2002; 71(4):863–876. [PubMed: 12215968]
253. Hinson JT, Fantin VR, Schonberger J, Breivik N, Siem G, McDonough B, Sharma P, Keogh I, Godinho R, Santos F, Esparza A, Nicolau Y, Selvaag E, Cohen BH, Hoppel CL, Tranebjaerg L, Eavey RD, Seidman JG, Seidman CE. Missense mutations in the BCS1L gene as a cause of the Bjornstad syndrome. *N Engl J Med.* 2007; 356(8):809–819. [PubMed: 17314340]
254. Conte L, Trumpower BL, Zara V. Bcs1p can rescue a large and productive cytochrome bc(1) complex assembly intermediate in the inner membrane of yeast mitochondria. *Biochim Biophys Acta.* 2010; 1813(1):91–101. [PubMed: 20727375]
255. Fontanesi F, Soto IC, Horn D, Barrientos A. Assembly of mitochondrial cytochrome c-oxidase, a complicated and highly regulated cellular process. *Am J Physiol Cell Physiol.* 2006; 291(6):C1129–C1147. [PubMed: 16760263]
256. Barrientos A, Korr D, Tzagoloff A. Shy1p is necessary for full expression of mitochondrial COX1 in the yeast model of Leigh's syndrome. *EMBO J.* 2002; 21(1–2):43–52. [PubMed: 11782424]
257. Broker S, Meunier B, Rich P, Gattermann N, Hofhaus G. MtDNA mutations associated with sideroblastic anaemia cause a defect of mitochondrial cytochrome c oxidase. *Eur J Biochem.* 1998; 258(1):132–138. [PubMed: 9851701]
258. Meunier B. Site-directed mutations in the mitochondrially encoded subunits I and III of yeast cytochrome oxidase. *Biochem J.* 2001; 354(Pt 2):407–412. [PubMed: 11171120]
259. Branden G, Gennis RB, Brzezinski P. Transmembrane proton translocation by cytochrome c oxidase. *Biochim Biophys Acta.* 2006; 1757(8):1052–1063. [PubMed: 16824482]
260. Williams SL, Scholte HR, Gray RG, Leonard JV, Schapira AH, Taanman JW. Immunological phenotyping of fibroblast cultures from patients with a mitochondrial respiratory chain deficit. *Lab Invest.* 2001; 81(8):1069–1077. [PubMed: 11502858]
261. Bratton M, Mills D, Castleden CK, Hosler J, Meunier B. Disease-related mutations in cytochrome c oxidase studied in yeast and bacterial models. *Eur J Biochem.* 2003; 270(6):1222–1230. [PubMed: 12631280]

262. Hoffbuhr KC, Davidson E, Filiano BA, Davidson M, Kennaway NG, King MP. A pathogenic 15-base pair deletion in mitochondrial DNA-encoded cytochrome c oxidase subunit III results in the absence of functional cytochrome c oxidase. *J Biol Chem.* 2000; 275(18):13994–14003. [PubMed: 10788526]
263. Massa V, Fernandez-Vizarra E, Alshahwan S, Bakhsh E, Goffrini P, Ferrero I, Mereghetti P, D'Adamo P, Gasparini P, Zeviani M. Severe infantile encephalomyopathy caused by a mutation in COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. *Am J Hum Genet.* 2008; 82(6):1281–1289. [PubMed: 18499082]
264. LaMarche AE, Abate MI, Chan SH, Trumpower BL. Isolation and characterization of COX12, the nuclear gene for a previously unrecognized subunit of *Saccharomyces cerevisiae* cytochrome c oxidase. *J Biol Chem.* 1992; 267(31):22473–22480. [PubMed: 1331057]
265. Barrientos A, Barros MH, Valnot I, Rotig A, Rustin P, Tzagoloff A. Cytochrome oxidase in health and disease. *Gene.* 2002; 286(1):53–63. [PubMed: 11943460]
266. Barrientos A, Gouget K, Horn D, Soto IC, Fontanesi F. Suppression mechanisms of COX assembly defects in yeast and human: insights into the COX assembly process. *Biochim Biophys Acta.* 2009; 1793(1):97–107. [PubMed: 18522805]
267. Petruzzella V, Tiranti V, Fernandez P, Ianna P, Carozzo R, Zeviani M. Identification and characterization of human cDNAs specific to BCS1, PET112, SCO1, COX15, and COX11, five genes involved in the formation and function of the mitochondrial respiratory chain. *Genomics.* 1998; 54(3):494–504. [PubMed: 9878253]
268. Siep M, van Oosterum K, Neufeglise H, van der Spek H, Grivell LA. Mss51p, a putative translational activator of cytochrome c oxidase subunit-1 (COX1) mRNA, is required for synthesis of Cox1p in *Saccharomyces cerevisiae*. *Curr Genet.* 2000; 37(4):213–220. [PubMed: 10803883]
269. Mick DU, Vukotic M, Piechura H, Meyer HE, Warscheid B, Deckers M, Rehling P. Coa3 and Cox14 are essential for negative feedback regulation of COX1 translation in mitochondria. *J Cell Biol.* 2010; 191(1):141–154. [PubMed: 20876281]
270. Perez-Martinez X, Broadley SA, Fox TD. Mss51p promotes mitochondrial Cox1p synthesis and interacts with newly synthesized Cox1p. *EMBO J.* 2003; 22(21):5951–5961. [PubMed: 14592991]
271. Mick DU, Wagner K, van der Laan M, Frazier AE, Perschil I, Pawlas M, Meyer HE, Warscheid B, Rehling P. Shy1 couples Cox1 translational regulation to cytochrome c oxidase assembly. *EMBO J.* 2007; 26(20):4347–4358. [PubMed: 17882259]
272. Pierrel F, Bestwick ML, Cobine PA, Khalimonchuk O, Cricco JA, Winge DR. Coa1 links the Mss51 post-translational function to Cox1 cofactor insertion in cytochrome c oxidase assembly. *EMBO J.* 2007; 26(20):4335–4346. [PubMed: 17882260]
273. Barros MH, Carlson CG, Glerum DM, Tzagoloff A. Involvement of mitochondrial ferredoxin and Cox15p in hydroxylation of heme O. *FEBS Lett.* 2001; 492(1–2):133–138. [PubMed: 11248251]
274. Bestwick M, Khalimonchuk O, Pierrel F, Winge DR. The role of Coa2 in hemylation of yeast Cox1 revealed by its genetic interaction with Cox10. *Mol Cell Biol.* 2010; 30(1):172–185. [PubMed: 19841065]
275. Hiser L, Di Valentin M, Hamer AG, Hosler JP. Cox11p is required for stable formation of the Cu(B) and magnesium centers of cytochrome c oxidase. *J Biol Chem.* 2000; 275(1):619–623. [PubMed: 10617659]
276. Khalimonchuk O, Bestwick M, Meunier B, Watts TC, Winge DR. Formation of the redox cofactor centers during Cox1 maturation in yeast cytochrome oxidase. *Mol Cell Biol.* 2010; 30(4):1004–1017. [PubMed: 19995914]
277. Pierrel F, Khalimonchuk O, Cobine PA, Bestwick M, Winge DR. Coa2 is an assembly factor for yeast cytochrome c oxidase biogenesis that facilitates the maturation of Cox1. *Mol Cell Biol.* 2008; 28(16):4927–4939. [PubMed: 18541668]
278. Beers J, Glerum DM, Tzagoloff A. Purification, characterization, and localization of yeast Cox17p, a mitochondrial copper shuttle. *J Biol Chem.* 1997; 272(52):33191–33196. [PubMed: 9407107]

279. Glerum DM, Shtanko A, Tzagoloff A. Characterization of COX17, a yeast gene involved in copper metabolism and assembly of cytochrome oxidase. *J Biol Chem.* 1996; 271(24):14504–14509. [PubMed: 8662933]
280. Mashkevich G, Repetto B, Glerum DM, Jin C, Tzagoloff A. SHY1, the yeast homolog of the mammalian SURF-1 gene, encodes a mitochondrial protein required for respiration. *J Biol Chem.* 1997; 272(22):14356–14364. [PubMed: 9162072]
281. Pequignot MO, Dey R, Zeviani M, Tiranti V, Godinot C, Poyau A, Sue C, Di Mauro S, Abitbol M, Marsac C. Mutations in the SURF1 gene associated with Leigh syndrome and cytochrome C oxidase deficiency. *Hum Mutat.* 2001; 17(5):374–381. [PubMed: 11317352]
282. Tiranti V, Corona P, Greco M, Taanman JW, Carrara F, Lamantea E, Nijtmans L, Uziel G, Zeviani M. A novel frameshift mutation of the mtDNA COIII gene leads to impaired assembly of cytochrome c oxidase in a patient affected by Leigh-like syndrome. *Hum Mol Genet.* 2000; 9(18):2733–2742. [PubMed: 11063732]
283. Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J, Chevrette M, Brown GK, Brown RM, Shoubbridge EA. SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. *Nat Genet.* 1998; 20(4):337–343. [PubMed: 9843204]
284. Bestwick M, Jeong MY, Khalimonchuk O, Kim H, Winge DR. Analysis of Leigh syndrome mutations in the yeast SURF1 homolog reveals a new member of the cytochrome oxidase assembly factor family. *Mol Cell Biol.* 2010; 30(18):4480–4491. [PubMed: 20624914]
285. Reinhold R, Bareth B, Balleininger M, Wissel M, Rehling P, Mick DU. Mimicking a SURF1 allele reveals uncoupling of cytochrome c oxidase assembly from translational regulation in yeast. *Hum Mol Genet.* 2011
286. Horng YC, Cobine PA, Maxfield AB, Carr HS, Winge DR. Specific copper transfer from the Cox17 metallochaperone to both Sco1 and Cox11 in the assembly of yeast cytochrome C oxidase. *J Biol Chem.* 2004; 279(34):35334–35340. [PubMed: 15199057]
287. Beers J, Glerum DM, Tzagoloff A. Purification and characterization of yeast Sco1p, a mitochondrial copper protein. *J Biol Chem.* 2002; 277(25):22185–22190. [PubMed: 11948192]
288. Nittis T, George GN, Winge DR. Yeast Sco1, a protein essential for cytochrome c oxidase function is a Cu(I)-binding protein. *J Biol Chem.* 2001; 276(45):42520–42526. [PubMed: 11546815]
289. Lode A, Kuschel M, Paret C, Rodel G. Mitochondrial copper metabolism in yeast: interaction between Sco1p and Cox2p. *FEBS Lett.* 2000; 485(1):19–24. [PubMed: 11086158]
290. Chinenov YV. Cytochrome c oxidase assembly factors with a thioredoxin fold are conserved among prokaryotes and eukaryotes. *J Mol Med.* 2000; 78(5):239–242. [PubMed: 10954195]
291. Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE, Krishna S, Walker W, Selby J, Glerum DM, Coster RV, Lyon G, Scalais E, Lebel R, Kaplan P, Shanske S, De Vivo DC, Bonilla E, Hirano M, DiMauro S, Schon EA. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. *Nat Genet.* 1999; 23(3):333–337. [PubMed: 10545952]
292. Leary SC, Kaufman BA, Pellicchia G, Guercin GH, Mattman A, Jaksch M, Shoubbridge EA. Human SCO1 and SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase. *Hum Mol Genet.* 2004; 13(17):1839–1848. [PubMed: 15229189]
293. Valnot I, Osmond S, Gigarel N, Mehaye B, Amiel J, Cormier-Daire V, Munnich A, Bonnefont JP, Rustin P, Rotig A. Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy. *Am J Hum Genet.* 2000; 67(5):1104–1109. [PubMed: 11013136]
294. Jaksch M, Ogilvie I, Yao J, Kortenhaus G, Bresser HG, Gerbitz KD, Shoubbridge EA. Mutations in SCO2 are associated with a distinct form of hypertrophic cardiomyopathy and cytochrome c oxidase deficiency. *Hum Mol Genet.* 2000; 9(5):795–801. [PubMed: 10749987]
295. Paret C, Ostermann K, Krause-Buchholz U, Rentzsch A, Rodel G. Human members of the SCO1 gene family: complementation analysis in yeast and intracellular localization. *FEBS Lett.* 1999; 447(1):65–70. [PubMed: 10218584]

296. Paret C, Lode A, Krause-Buchholz U, Rodel G. The P(174)L mutation in the human hSCO1 gene affects the assembly of cytochrome c oxidase. *Biochem Biophys Res Commun.* 2000; 279(2): 341–347. [PubMed: 11118289]
297. Dickinson EK, Adams DL, Schon EA, Glerum DM. A human SCO2 mutation helps define the role of Sco1p in the cytochrome oxidase assembly pathway. *J Biol Chem.* 2000; 275(35):26780–26785. [PubMed: 10854440]
298. Antonicka H, Leary SC, Guercin GH, Agar JN, Horvath R, Kennaway NG, Harding CO, Jaksch M, Shoubbridge EA. Mutations in COX10 result in a defect in mitochondrial heme A biosynthesis and account for multiple, early-onset clinical phenotypes associated with isolated COX deficiency. *Hum Mol Genet.* 2003; 12(20):2693–2702. [PubMed: 12928484]
299. Antonicka H, Mattman A, Carlson CG, Glerum DM, Hoffbuhr KC, Leary SC, Kennaway NG, Shoubbridge EA. Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy. *Am J Hum Genet.* 2003; 72(1): 101–114. [PubMed: 12474143]
300. Velours J, Arselin G. The *Saccharomyces cerevisiae* ATP synthase. *J Bioenerg Biomembr.* 2000; 32(4):383–390. [PubMed: 11768300]
301. Houstek J, Pickova A, Vojtiskova A, Mracek T, Pecina P, Jesina P. Mitochondrial diseases and genetic defects of ATP synthase. *Biochim Biophys Acta.* 2006; 1757(9–10):1400–1405. [PubMed: 16730639]
302. Rak M, Tetaud E, Duvezin-Caubet S, Ezkurdia N, Bietenhader M, Rytka J, di Rago JP. A yeast model of the neurogenic ataxia retinitis pigmentosa (NARP) T8993G mutation in the mitochondrial ATP synthase-6 gene. *J Biol Chem.* 2007; 282(47):34039–34047. [PubMed: 17855363]
303. Kucharczyk R, Rak M, di Rago JP. Biochemical consequences in yeast of the human mitochondrial DNA 8993T>C mutation in the ATPase6 gene found in NARP/MILS patients. *Biochim Biophys Acta.* 2009; 1793(5):817–824. [PubMed: 19269308]
304. Kucharczyk R, Salin B, di Rago JP. Introducing the human Leigh syndrome mutation T9176G into *Saccharomyces cerevisiae* mitochondrial DNA leads to severe defects in the incorporation of Atp6p into the ATP synthase and in the mitochondrial morphology. *Hum Mol Genet.* 2009; 18(15):2889–2898. [PubMed: 19454486]
305. Kucharczyk R, Ezkurdia N, Couplan E, Procaccio V, Ackerman SH, Blondel M, di Rago JP. Consequences of the pathogenic T9176C mutation of human mitochondrial DNA on yeast mitochondrial ATP synthase. *Biochim Biophys Acta.* 2010; 1797(6–7):1105–1112. [PubMed: 20056103]
306. Ackerman SH, Tzagoloff A. Identification of two nuclear genes (ATP11, ATP12) required for assembly of the yeast F1-ATPase. *Proc Natl Acad Sci U S A.* 1990; 87(13):4986–4990. [PubMed: 2142305]
307. Rak M, Zeng X, Briere JJ, Tzagoloff A. Assembly of F0 in *Saccharomyces cerevisiae*. *Biochim Biophys Acta.* 2009; 1793(1):108–116. [PubMed: 18672007]
308. Wang ZG, White PS, Ackerman SH. Atp11p and Atp12p are assembly factors for the F(1)-ATPase in human mitochondria. *J Biol Chem.* 2001; 276(33):30773–30778. [PubMed: 11410595]
309. Wang ZG, Sheluho D, Gatti DL, Ackerman SH. The alpha-subunit of the mitochondrial F(1) ATPase interacts directly with the assembly factor Atp12p. *EMBO J.* 2000; 19(7):1486–1493. [PubMed: 10747017]
310. De Meirleir L, Seneca S, Lissens W, De Clercq I, Eyskens F, Gerlo E, Smet J, Van Coster R. Respiratory chain complex V deficiency due to a mutation in the assembly gene ATP12. *J Med Genet.* 2004; 41(2):120–124. [PubMed: 14757859]
311. Ackerman SH. Atp11p and Atp12p are chaperones for F(1)-ATPase biogenesis in mitochondria. *Biochim Biophys Acta.* 2002; 1555(1–3):101–105. [PubMed: 12206899]
312. Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, Mandel JL, Brice A, Koenig M. Clinical and genetic abnormalities in patients with Friedreich's ataxia. *N Engl J Med.* 1996; 335(16):1169–1175. [PubMed: 8815938]

313. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Canizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Coccozza S, Koenig M, Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. *Science*. 1996; 271(5254):1423–1427. [PubMed: 8596916]
314. Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, Pandolfo M, Kaplan J. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. *Science*. 1997; 276(5319):1709–1712. [PubMed: 9180083]
315. Wilson RB, Roof DM. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. *Nat Genet*. 1997; 16(4):352–357. [PubMed: 9241271]
316. Foury F, Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. *FEBS Lett*. 1997; 411(2–3):373–377. [PubMed: 9271239]
317. Knight SA, Sepuri NB, Pain D, Dancis A. Mt-Hsp70 homolog, Ssc2p, required for maturation of yeast frataxin and mitochondrial iron homeostasis. *J Biol Chem*. 1998; 273(29):18389–18393. [PubMed: 9660806]
318. Bradley JL, Blake JC, Chamberlain S, Thomas PK, Cooper JM, Schapira AH. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. *Hum Mol Genet*. 2000; 9(2):275–282. [PubMed: 10607838]
319. Cavadini P, Gellera C, Patel PI, Isaya G. Human frataxin maintains mitochondrial iron homeostasis in *Saccharomyces cerevisiae*. *Hum Mol Genet*. 2000; 9(17):2523–2530. [PubMed: 11030757]
320. Adamec J, Rusnak F, Owen WG, Naylor S, Benson LM, Gacy AM, Isaya G. Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. *Am J Hum Genet*. 2000; 67(3):549–562. [PubMed: 10930361]
321. Gakh O, Smith DYt, Isaya G. Assembly of the iron-binding protein frataxin in *Saccharomyces cerevisiae* responds to dynamic changes in mitochondrial iron influx and stress level. *J Biol Chem*. 2008; 283(46):31500–31510. [PubMed: 18784075]
322. Park S, Gakh O, O'Neill HA, Mangravita A, Nichol H, Ferreira GC, Isaya G. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. *J Biol Chem*. 2003; 278(33):31340–31351. [PubMed: 12732649]
323. Gonzalez-Cabo P, Vazquez-Manrique RP, Garcia-Gimeno MA, Sanz P, Palau F. Frataxin interacts functionally with mitochondrial electron transport chain proteins. *Hum Mol Genet*. 2005; 14(15):2091–2098. [PubMed: 15961414]
324. Gerber J, Muhlenhoff U, Lill R. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. *EMBO Rep*. 2003; 4(9):906–911. [PubMed: 12947415]
325. Chen OS, Hemenway S, Kaplan J. Inhibition of Fe-S cluster biosynthesis decreases mitochondrial iron export evidence that Yfh1p affects Fe-S cluster synthesis. *Proc Natl Acad Sci U S A*. 2002; 99(19):12321–12326. [PubMed: 12221295]
326. Rotig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. *Nat Genet*. 1997; 17(2): 215–217. [PubMed: 9326946]
327. Bulteau AL, O'Neill HA, Kennedy MC, Ikeda-Saito M, Isaya G, Szweda LI. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. *Science*. 2004; 305(5681): 242–245. [PubMed: 15247478]
328. Schlame M, Haldar D. Cardiolipin is synthesized on the matrix side of the inner membrane in rat liver mitochondria. *J Biol Chem*. 1993; 268(1):74–79. [PubMed: 8380172]
329. Schlame M, Rua D, Greenberg ML. The biosynthesis and functional role of cardiolipin. *Prog Lipid Res*. 2000; 39(3):257–288. [PubMed: 10799718]
330. Schlame M, Ren M. Barth syndrome, a human disorder of cardiolipin metabolism. *FEBS Lett*. 2006; 580(23):5450–5455. [PubMed: 16973164]

331. Beranek A, Rechberger G, Knauer H, Wolinski H, Kohlwein SD, Leber R. Identification of a cardiolipin-specific phospholipase encoded by the gene CLD1 (YGR110W) in yeast. *J Biol Chem.* 2009; 284(17):11572–11578. [PubMed: 19244244]
332. Xu Y, Malhotra A, Ren M, Schlame M. The enzymatic function of tafazzin. *J. Biol. Chem.* 2006; 281(51):39217–39224. [PubMed: 17082194]
333. Schlame M, Ren M, Xu Y, Greenberg ML, Haller I. Molecular symmetry in mitochondrial cardiolipins. *Chem. Phys. Lipids.* 2005; 138(1–2):38–49. [PubMed: 16226238]
334. Claypool SM, Koehler CM. The complexity of cardiolipin in health and disease. *Trends Biochem Sci.* 2011
335. Kutik S, Rissler M, Guan XL, Guiard B, Shui G, Gebert N, Heacock PN, Rehling P, Dowhan W, Wenk MR, Pfanner N, Wiedemann N. The translocator maintenance protein Tam41 is required for mitochondrial cardiolipin biosynthesis. *J Cell Biol.* 2008; 183(7):1213–1221. [PubMed: 19114592]
336. Marom M, Safonov R, Amram S, Avneon Y, Nachliel E, Gutman M, Zohary K, Azem A, Tsfadia Y. Interaction of the Tim44 C-terminal domain with negatively charged phospholipids. *Biochemistry.* 2009; 48(47):11185–11195. [PubMed: 19863062]
337. van der Laan M, Meinecke M, Dudek J, Hutu DP, Lind M, Perschil I, Guiard B, Wagner R, Pfanner N, Rehling P. Motor-free mitochondrial presequence translocase drives membrane integration of preproteins. *Nat Cell Biol.* 2007; 9(10):1152–1159. [PubMed: 17828250]
338. Lionaki E, de Marcos Lousa C, Baud C, Vougioukalaki M, Panayotou G, Tokatlidis K. The essential function of Tim12 *in vivo* is ensured by the assembly interactions of its C-terminal domain. *J Biol Chem.* 2008; 283(23):15747–15753. [PubMed: 18387953]
339. Beyer K, Klingenberg M. ADP/ATP carrier protein from beef heart mitochondria has high amounts of tightly bound cardiolipin, as revealed by ³¹P nuclear magnetic resonance. *Biochemistry.* 1985; 24(15):3821–3826. [PubMed: 2996583]
340. Beyer K, Nüscher B. Specific cardiolipin binding interferes with labeling of sulfhydryl residues in the adenosine diphosphate/adenosine triphosphate carrier protein from beef heart mitochondria. *Biochemistry.* 1996; 35(49):15784–15790. [PubMed: 8961941]
341. Brandolin G, Doussière J, Gulik A, Gulik-Krzywicki T, Lauquin GJ, Vignais PV. Kinetic, binding and ultrastructural properties of the beef heart adenine nucleotide carrier protein after incorporation into phospholipid vesicles. *Biochim. Biophys. Acta.* 1980; 592(3):592–614. [PubMed: 6251872]
342. Fiermonte G, Dolce V, Palmieri F. Expression in *Escherichia coli*, functional characterization, and tissue distribution of isoforms A and B of the phosphate carrier from bovine mitochondria. *J. Biol. Chem.* 1998; 273(35):22782–22787. [PubMed: 9712911]
343. Hoffmann B, Stockl A, Schlame M, Beyer K, Klingenberg M. The reconstituted ADP/ATP carrier activity has an absolute requirement for cardiolipin as shown in cysteine mutants. *J. Biol. Chem.* 1994; 269(3):1940–1944. [PubMed: 8294444]
344. Indiveri C, Tonazzi A, Palmieri F. Identification and purification of the ornithine/citrulline carrier from rat liver mitochondria. *Eur. J. Biochem.* 1992; 207(2):449–454. [PubMed: 1633803]
345. Indiveri C, Tonazzi A, Prezioso G, Palmieri F. Kinetic characterization of the reconstituted carnitine carrier from rat liver mitochondria. *Biochim. Biophys. Acta.* 1991; 1065(2):231–238. [PubMed: 2059655]
346. Kadenbach B, Mende P, Kolbe HV, Stipani I, Palmieri F. The mitochondrial phosphate carrier has an essential requirement for cardiolipin. *FEBS Lett.* 1982; 139(1):109–112. [PubMed: 7075760]
347. Kramer R, Klingenberg M. Enhancement of reconstituted ADP,ATP exchange activity by phosphatidylethanolamine and by anionic phospholipids. *FEBS Lett.* 1980; 119(2):257–260. [PubMed: 7428937]
348. Noel H, Pande SV. An essential requirement of cardiolipin for mitochondrial carnitine acylcarnitine translocase activity. Lipid requirement of carnitine acylcarnitine translocase. *Eur. J. Biochem.* 1986; 155(1):99–102. [PubMed: 3948883]

349. Nury H, Dahout-Gonzalez C, Trezeguet V, Lauquin G, Brandolin G, Pebay-Peyroula E. Structural basis for lipid-mediated interactions between mitochondrial ADP/ATP carrier monomers. *FEBS Lett.* 2005; 579(27):6031–6036. [PubMed: 16226253]
350. Pebay-Peyroula E, Dahout-Gonzalez C, Kahn R, Trezeguet V, Lauquin GJ, Brandolin G. Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside. *Nature.* 2003; 426(6962):39–44. [PubMed: 14603310]
351. Vyssokikh MY, Brdiczka D. The function of complexes between the outer mitochondrial membrane pore (VDAC) and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis. *Acta. Biochim. Pol.* 2003; 50(2):389–404. [PubMed: 12833165]
352. Eble KS, Coleman WB, Hantgan RR, Cunningham CC. Tightly associated cardiolipin in the bovine heart mitochondrial ATP synthase as analyzed by ³¹P nuclear magnetic resonance spectroscopy. *J. Biol. Chem.* 1990; 265(32):19434–19440. [PubMed: 2147180]
353. Fry M, Green D. Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain. *J. Biol. Chem.* 1981; 256(4):1874–1880. [PubMed: 6257690]
354. Gomez B Jr, Robinson NC. Quantitative determination of cardiolipin in mitochondrial electron transferring complexes by silicic acid high-performance liquid chromatography. *Anal. Biochem.* 1999; 267(1):212–216. [PubMed: 9918673]
355. Gomez B Jr, Robinson NC. Phospholipase digestion of bound cardiolipin reversibly inactivates bovine cytochrome bc1. *Biochemistry.* 1999; 38(28):9031–9038. [PubMed: 10413476]
356. Lange C, Nett JH, Trumpower BL, Hunte C. Specific roles of protein-phospholipid interactions in the yeast cytochrome bc1 complex structure. *EMBO J.* 2001; 20(23):6591–6600. [PubMed: 11726495]
357. Sedlak E, Robinson NC. Phospholipase A(2) digestion of cardiolipin bound to bovine cytochrome c oxidase alters both activity and quaternary structure. *Biochemistry.* 1999; 38(45):14966–14972. [PubMed: 10555978]
358. Shinzawa-Itoh K, Aoyama H, Muramoto K, Terada H, Kurauchi T, Tadehara Y, Yamasaki A, Sugimura T, Kurono S, Tsujimoto K, Mizushima T, Yamashita E, Tsukihara T, Yoshikawa S. Structures and physiological roles of 13 integral lipids of bovine heart cytochrome c oxidase. *EMBO J.* 2007; 26(6):1713–1725. [PubMed: 17332748]
359. Vik SB, Georgevich G, Capaldi RA. Diphosphatidylglycerol is required for optimal activity of beef heart cytochrome c oxidase. *Proc. Natl. Acad. Sci. U S A.* 1981; 78(3):1456–1460. [PubMed: 6262802]
360. Koshkin V, Greenberg ML. Oxidative phosphorylation in cardiolipin-lacking yeast mitochondria. *Biochem J.* 2000; 347(Pt 3):687–691. [PubMed: 10769171]
361. Jiang F, Ryan MT, Schlame M, Zhao M, Gu Z, Klingenberg M, Pfanner N, Greenberg ML. Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. *J Biol Chem.* 2000; 275(29):22387–22394. [PubMed: 10777514]
362. Zhang M, Mileykovskaya E, Dowhan W. Cardiolipin is essential for organization of complexes III and IV into a supercomplex in intact yeast mitochondria. *J Biol Chem.* 2005; 280(33):29403–29408. [PubMed: 15972817]
363. Zhang M, Mileykovskaya E, Dowhan W. Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. *J Biol Chem.* 2002; 277(46):43553–43556. [PubMed: 12364341]
364. Pfeiffer K, Gohil V, Stuart RA, Hunte C, Brandt U, Greenberg ML, Schagger H. Cardiolipin stabilizes respiratory chain supercomplexes. *J Biol Chem.* 2003; 278(52):52873–52880. [PubMed: 14561769]
365. Cruciat CM, Brunner S, Baumann F, Neupert W, Stuart RA. The cytochrome bc1 and cytochrome c oxidase complexes associate to form a single supracomplex in yeast mitochondria. *J Biol Chem.* 2000; 275(24):18093–18098. [PubMed: 10764779]
366. Schagger H, Pfeiffer K. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. *EMBO J.* 2000; 19(8):1777–1783. [PubMed: 10775262]

367. Heinemeyer J, Braun HP, Boekema EJ, Kouril R. A structural model of the cytochrome C reductase/oxidase supercomplex from yeast mitochondria. *J Biol Chem.* 2007; 282(16):12240–12248. [PubMed: 17322303]
368. Claypool SM, Oktay Y, Boontheung P, Loo JA, Koehler CM. Cardiolipin defines the interactome of the major ADP/ATP carrier protein of the mitochondrial inner membrane. *J. Cell Biol.* 2008; 182(5):937–950. [PubMed: 18779372]
369. Barth PG, Scholte HR, Berden JA, Van der Klei-Van Moorsel JM, Luyt-Houwen IE, Van 't Veer-Korthof ET, Van der Harten JJ, Sobotka-Plojhar MA. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. *J. Neurol. Sci.* 1983; 62(1–3):327–355. [PubMed: 6142097]
370. Ades LC, Gedeon AK, Wilson MJ, Latham M, Partington MW, Mulley JC, Nelson J, Lui K, Sillence DO. Barth syndrome: clinical features and confirmation of gene localisation to distal Xq28. *Am J Med Genet.* 1993; 45(3):327–334. [PubMed: 8434619]
371. Barth PG, Van den Bogert C, Bolhuis PA, Scholte HR, van Gennip AH, Schutgens RB, Ketel AG. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): respiratory-chain abnormalities in cultured fibroblasts. *J Inherit Metab Dis.* 1996; 19(2):157–160. [PubMed: 8739954]
372. Christodoulou J, McInnes RR, Jay V, Wilson G, Becker LE, Lehotay DC, Platt BA, Bridge PJ, Robinson BH, Clarke JT. Barth syndrome: clinical observations and genetic linkage studies. *Am J Med Genet.* 1994; 50(3):255–264. [PubMed: 8042670]
373. McKenzie M, Lazarou M, Thorburn DR, Ryan MT. Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients. *J Mol Biol.* 2006; 361(3):462–469. [PubMed: 16857210]
374. Schlame M, Kelley RI, Feigenbaum A, Towbin JA, Heerdt PM, Schieble T, Wanders RJ, DiMauro S, Blanck TJ. Phospholipid abnormalities in children with Barth syndrome. *J Am Coll Cardiol.* 2003; 42(11):1994–1999. [PubMed: 14662265]
375. Valianpour F, Mitsakos V, Schlemmer D, Towbin JA, Taylor JM, Ekert PG, Thorburn DR, Munnich A, Wanders RJ, Barth PG, Vaz FM. Monolysocardiolipins accumulate in Barth syndrome but do not lead to enhanced apoptosis. *J Lipid Res.* 2005; 46(6):1182–1195. [PubMed: 15805542]
376. Claypool SM, McCaffery JM, Koehler CM. Mitochondrial mislocalization and altered assembly of a cluster of Barth syndrome mutant tafazzins. *J Cell Biol.* 2006; 174(3):379–390. [PubMed: 16880272]
377. Claypool SM, Whited K, Srijumng S, Han X, Koehler CM. Barth syndrome mutations that cause tafazzin complex lability. *J Cell Biol.* 2011; 192(3):447–462. [PubMed: 21300850]
378. Gu Z, Valianpour F, Chen S, Vaz FM, Hakkaart GA, Wanders RJ, Greenberg ML. Aberrant cardiolipin metabolism in the yeast taz1 mutant: a model for Barth syndrome. *Mol Microbiol.* 2004; 51(1):149–158. [PubMed: 14651618]
379. Testet E, Laroche-Traineau J, Noubhani A, Coulon D, Bunoust O, Camougrand N, Manon S, Lessire R, Bessoule JJ. Ypr140wp, 'the yeast tafazzin', displays a mitochondrial lysophosphatidylcholine (lyso-PC) acyltransferase activity related to triacylglycerol and mitochondrial lipid synthesis. *Biochem J.* 2005; 387(Pt 3):617–626. [PubMed: 15588229]
380. Vaz FM, Houtkooper RH, Valianpour F, Barth PG, Wanders RJ. Only one splice variant of the human TAZ gene encodes a functional protein with a role in cardiolipin metabolism. *J Biol Chem.* 2003; 278(44):43089–43094. [PubMed: 12930833]
381. Brandner K, Mick DU, Frazier AE, Taylor RD, Meisinger C, Rehling P. Taz1, an outer mitochondrial membrane protein, affects stability and assembly of inner membrane protein complexes: implications for Barth Syndrome. *Mol Biol Cell.* 2005; 16(11):5202–5214. [PubMed: 16135531]
382. Claypool SM, Boontheung P, McCaffery JM, Loo JA, Koehler CM. The cardiolipin transacylase, tafazzin, associates with two distinct respiratory components providing insight into Barth syndrome. *Mol Biol Cell.* 2008; 19(12):5143–5155. [PubMed: 18799610]
383. Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D. A novel X-linked gene, G4.5, is responsible for Barth syndrome. *Nat Genet.* 1996; 12(4):385–389. [PubMed: 8630491]

384. Ma L, Vaz FM, Gu Z, Wanders RJ, Greenberg ML. The human TAZ gene complements mitochondrial dysfunction in the yeast *taz1Delta* mutant. Implications for Barth syndrome. *J Biol Chem.* 2004; 279(43):44394–44399. [PubMed: 15304507]
385. Chang SC, Heacock PN, Clancey CJ, Dowhan W. The PEL1 gene (renamed PGS1) encodes the phosphatidylglycero-phosphate synthase of *Saccharomyces cerevisiae*. *J Biol Chem.* 1998; 273(16):9829–9836. [PubMed: 9545322]
386. Osman C, Haag M, Wieland FT, Brugger B, Langer T. A mitochondrial phosphatase required for cardiolipin biosynthesis: the PGP phosphatase Gep4. *EMBO J.* 29(12):1976–1987. [PubMed: 20485265]

Figure 1.

Summary of OXPHOS in yeast and the multitude of patient phenotypes associated with pathogenic lesions that impact each individual complex. Complex II (brown), also referred to as SDH, is a physical link between the TCA cycle and the electron transport chain. Electrons derived from the oxidation of succinate to fumarate by Complex II ultimately reduce CoQ (QH₂). QH₂ engages one of two CoQ binding sites within Complex III (pink) where its two electrons reach a fork in the road. One electron ultimately reduces cytochrome *c* while the other electron is delivered to oxidized CoQ (Q) in the 2nd CoQ binding site within Complex III producing a reactive semiquinone. The semiquinone is fully reduced to QH₂ upon the release of a second wave of electrons from another QH₂ completing the Q cycle. The release of electrons by QH₂ is coupled to the discharge of H⁺ into the IMS. Reduced cytochrome *c* donates its single electron to Complex IV (grey) which couples the reduction of O₂ to H₂O with the vectorial transport of H⁺ into the IMS. Complexes III and IV assemble in supercomplexes that increase the efficiency of the electron transport chain by substrate channeling. The proton-motive force established by Complex III and IV is harnessed by the Complex V (aka the ATP synthase) to produce ATP. The numerous

phenotypes observed in patients with mutations associated with each individual OXPHOS complex is indicated.

Figure 2.

Two non-mutually exclusive models of how mutations in SDH promote tumorigenesis. (A) SDH is a nexus between the TCA cycle and the electron transport chain. In the TCA cycle, it oxidizes succinate to fumarate. The two released hydrogens in turn reduce the FAD cofactor associated with SDHA/Sdh1p. Electrons are transferred from FADH₂ to a series of three Fe/S clusters in SDHB/Sdh2p and ultimately to oxidized CoQ (Q) generating reduced CoQ (QH₂) which donates its electrons to Complex III. In the cytosol, HIF-1 alpha is rapidly degraded subsequent to its prolyl hydroxylation (degradation indicated by faded coloring). (B) Mutations in SDH result in an accumulation of succinate which is transported into the cytosol by the dicarboxylate carrier in exchange for P_i. If the pathogenic mutation occurs in a subunit other than SDHA/Sdh1p, the flow of electrons is uncoupled from the reduction of CoQ and ROS are generated. ROS and succinate can both inhibit HIF-1 alpha prolyl hydroxylases leading to HIF-1 alpha stabilization. HIF-1 alpha induces the expression of genes involved in angiogenesis, proliferation, cell survival, and glycolysis; pathways that would benefit a tumor.

Figure 3.

CL structure and schematic showing CL assembly and remodeling pathways in mitochondria. (A) Structure of CL. The position of the four attached acyl chains is indicated (R_1 thru R_4). (B) CL biosynthetic (*boxed in yellow*) and remodeling (*boxed in blue*) pathways. Pgs1p catalyzes the first and committed step in CL biosynthesis producing phosphatidylglycerophosphate from CDP-DAG and G3P (385). The recently identified phosphatidylglycerophosphate phosphatase, Gep4 (386), generates phosphatidylglycerol, the precursor of “immature” CL. Finally, “immature” CL is produced by Crd1p from phosphatidylglycerol and CDP-DAG. The acyl chains of “immature” CL are remodeled by the sequential action of the CL deacylase, Cld1p, and MLCL transacylase, Taz1p. The

difference in acyl chain composition between “immature” and “mature” CL is illustrated on the right. CDP-DAG, cytidine diphosphatediphosphate-diacylglycerol; CMP, cytidine monophosphate; G3P, glycerol-3-phosphate; FA, fatty acid; PC, phosphatidylcholine; lyso-PC, lyso- phosphatidylcholine.

The Power of Yeast as a Model for Mitochondrial Disease

Figure 4.

The power of yeast as a model for human mitochondrial disease. When the weaknesses of the yeast model (unicellular, absence of respiratory complex I, and homoplasmic mtDNA) are directly compared to its strengths (high degree of conservation of basic mitochondrial processes, easy genetics, robust biochemistry, ability to survive in the absence of a functional OXPHOS system, homoplasmic mtDNA, and capacity for large scale genetic, pharmacologic, and suppressor screens) with respect to modeling human mitochondrial disease, the value of yeast is clearly evident.

Table 1

Genes involved in mitochondrial disease and their yeast orthologs

Mitochondrial function	Human gene	Yeast gene	Molecular function	Molecular consequences of dysfunction	Clinical manifestations ¹
mtDNA	<i>POLG</i>	<i>MIP1</i>	mtDNA polymerase	mtDNA depletion, increased mtDNA mutability	PEO, Alpers Syndrome, ataxia- neuropathy syndrome
	<i>ANT1</i>	<i>AAC2</i>	ATP/ADP carrier	mtDNA depletion, abnormal ATP/ADP transport, loss of membrane potential	autosomal dominant PEO, hypertrophic cardiomyopathy, myopathy, exercise intolerance, lactic acidosis
	<i>MPV17</i>	<i>SYM1</i>	unknown	mtDNA depletion, abnormal mitochondrial morphology, ethanol intolerance	moderate to severe liver dysfunction
	<i>GFER</i>	<i>ERV1</i>	part of the disulfide relay system. Oxidizes Mia40p, donates electrons to cytochrome c.	respiratory defect at elevated temperature, COX activity decreased, mtDNA deletions	hypotonia, hearing loss, congenital cataract, developmental delay
Protein import	<i>DDP1</i>	<i>TIM8</i>	IMS chaperone of Tim23p precursor	reduced abundance of import substrates	Mohr-Tranebjaerg syndrome
	<i>MFN1 MFN2</i>	<i>FZO1</i>	GTPase mediating OM fusion	fragmented or aggregated mitochondria, respiratory defect	Charcot-Marie-Tooth disease type 2A
Dynamics	<i>OPA1</i>	<i>MGM1</i>	dynammin-related GTPase mediating IM fusion	fragmented or aggregated mitochondria, respiratory defect	dominant optic neuropathy
	<i>DRP1</i>	<i>DNM1</i>	dynammin-related GTPase mediating mitochondrial fission	elongated, tubular mitochondrial network	abnormal brain development, optic atrophy, hypotonia, elevated lactate levels
Proteases	<i>AFG3L2</i>	<i>YTA10/12</i>	m-AAA metalloprotease involved in precursor processing and quality control	unprocessed protein precursors, respiratory defect	autosomal dominant spinocerebellar ataxia
	<i>SPG7</i>	<i>YTA10/12</i>	m-AAA metalloprotease involved in precursor processing and quality control	unprocessed protein precursors, respiratory defect	spastic paraplegia
Respiratory complex subunits	<i>SDHA</i>	<i>SDH1</i>	flavoprotein subunit of succinate dehydrogenase	loss of SDH activity	Leigh syndrome, paraganglioma
	<i>SDHB</i>	<i>SDH2</i>	Fe/S subunit of succinate dehydrogenase	loss of SDH activity	paragangliomas, pheochromocytomas
	<i>SDHC</i>	<i>SDH3</i>	membrane anchor subunit of succinate dehydrogenase	loss of SDH activity	paragangliomas, pheochromocytomas
	<i>SDHD</i>	<i>SDH4</i>	membrane anchor subunit of succinate dehydrogenase	loss of SDH activity	paragangliomas, pheochromocytomas
	<i>CYTB</i>	<i>COB</i>	catalytic subunit of complex III	no complex III activity	MILS, Kearns-Sayre syndrome, MELAS, Leber's hereditary optic neuropathy, cardiomyopathy, myopathy, exercise intolerance

Mitochondrial function	Human gene	Yeast gene	Molecular function	Molecular consequences of dysfunction	Clinical manifestations ¹
	<i>COX1</i>	<i>COX1</i>	catalytic subunit of complex IV	COX deficiency	Leigh syndrome, MELAS, encephalomyopathy, myopathy
	<i>COX2</i>	<i>COX2</i>	catalytic subunit of complex IV	COX deficiency	Leigh syndrome, MELAS, encephalomyopathy, myopathy
	<i>COX3</i>	<i>COX3</i>	subunit of complex IV	COX deficiency	Leigh syndrome, MELAS, encephalomyopathy, myopathy
	<i>COX6B</i>	<i>COX12</i>	subunit of complex IV	COX deficiency	infantile encephalomyopathy
	<i>ATP6</i>	<i>ATP6</i>	subunit of ATP synthase	decreased ATP synthesis	MILS, NARP
Respiratory complex assembly factors	<i>SDHAF1</i>	<i>SDH6</i>	involved in SDH assembly	decrease in SDH activity	infantile leukoencephalopathy
	<i>SDHAF2</i>	<i>SDH5</i>	SDHA flavination	no SDH activity	paraganglioma
	<i>BCS1L</i>	<i>BCS1</i>	incorporates Rip1 into complex III	reduced complex III activity	complex III deficiency, GRACILE syndrome, Björnstad syndrome
	<i>SURF1</i>	<i>SHY1</i>	involved in complex IV assembly, may stabilize Cox1p	reduced complex IV activity	Leigh syndrome
	<i>SCO1</i>	<i>SCO1</i>	transfer of Cu or cysteine reduction in Cox2p	reduced complex IV activity	hepatopathy and ketoacidotic coma
	<i>SCO2</i>	<i>SCO1</i>	transfer of Cu or cysteine reduction in Cox2p	reduced complex IV activity	infantile cardiomyopathy
	<i>ATP12</i>	<i>ATP12</i>	assembly of F1 portion of ATP synthase	reduced ATP synthesis, reduced activity of other respiratory complexes	lactic acidosis, dysmorphic features, methyl glutaconic aciduria and early death
Iron regulation	<i>FXN</i>	<i>YFH1</i>	iron chaperone, formation of Fe-S clusters	mitochondrial iron accumulation, mtDNA instability	Friedreich ataxia
Lipid remodeling	<i>TAZ</i>	<i>TAZ1</i>	CL transacylase	decreased CL abundance, increased MLCL levels, respiratory defects	Barth syndrome

¹ A description of the clinical phenotypes associated with each disease can be found in the text and references therein